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Abstract 
	  
 Branched-chain amino acids (BCAAs) act as effector molecules that signal a global 
transcriptional regulator, CodY, to regulate virulence factors in nutrient depleted 
environments. Staphylococcus aureus contains three putative BCAA transporters (BrnQ1, 
BrnQ2, BrnQ3) whose role in BCAA uptake is unknown. We hypothesize that BrnQ 
transporters are involved in BCAA uptake and contribute to virulence in S. aureus by 
modulating CodY activity. Results from radioactive uptake assays indicate that BrnQ1 is the 
predominant BrnQ transporter of isoleucine, valine and leucine. Meanwhile, BrnQ2 is more 
specific for isoleucine. Furthermore, only the lack of BrnQ1 hinders growth of S. aureus in 
chemically-defined media with limited concentrations of BCAAs; however, BrnQ2 and 
BrnQ3 show no such growth phenotype. In vivo, the brnQ1 and brnQ3 mutants are 
attenuated for virulence in a mouse model of bacteremia, but the brnQ2 mutant was hyper-
virulent, suggesting that the gene plays a more important role within the host.  
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1.1. The Staphylococci 
 
1.1.1. The genus Staphylococcus 	  
The staphylococci are part of the family of gram-positive cocci, Staphylococcaceae. 
The term “staphylococcus” is a derivative of the Greek word staphylé, meaning, “bunch of 
grapes”, because of their formation of grape-like clusters. The term “coccus,” means grain or 
berry. Presently, there are 32 species and eight sub-species in the genus Staphylococcus, 
many of which are colonizers of the human body (64), however the two most well-
characterized species are Staphylococcus aureus and Staphylococcus epidermidis.  
 
1.1.2. Characteristics of staphylococci 
The staphylococci are non-motile, non-spore forming facultative anaerobes that grow 
most rapidly under aerobic conditions and in the presence of CO2. They are also catalase-
positive and oxidase-negative, differentiating them from the streptococci, which are catalase-
negative (142). Pathogenic staphylococci can be identified by their production of coagulase, 
which causes plasma to coagulate by converting fibrinogen into fibrin (65). This 
distinguishes S. aureus, a coagulase positive species, from more than 30 species of coagulase 
negative staphylococci (CoNS), of which S. epidermidis is perhaps the most well known.  
Staphylococci have a diameter of 0.7–1.2 µm and have a gram-positive cell wall. 
Their ability to form clusters is due to cell division taking place in more than one plane. S. 
aureus forms medium-sized “golden” colonies on rich medium. S. aureus forms β-hemolytic 
colonies on sheep blood agar, due to the production of several hemolysins such as α-toxin, β-
toxin, γ-toxin, and δ-toxin. Some S. epidermidis strains can also be β-hemolytic due to the 
production of δ-toxin (131). Moreover, pigmentation of S. aureus is more prominent after 24 
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hours of growth and when incubated at room temperature (60, 143). In S. aureus, the golden 
pigmentation of the colonies is caused by carotenoids, whose biosynthetic pathway has 
recently been determined (107). Moreover, the carotenoids have been shown to act as 
virulence factors, due to their ability to protect the pathogen from oxidants produced by the 
immune system (79). 
Staphylococci have the ability to grow in a wide pH range (4.8–9.4), are resistant to 
drying, and can persist even at extremely high temperatures. Moreover, S. aureus can tolerate 
high-salt concentrations (7.5–10% NaCl) due to the production of osmoprotectants (142). 
The ability of S. aureus to ferment mannitol permits it to be differentiated from CoNS such 
as S. epidermidis and S. saprophyticus. In addition, S. aureus can also metabolize various 
other carbon sources such as glucose, lactose, xylose, sucrose, maltose, and glycerol. 
Moreover, growing the cells in the presence of novobiocin can further differentiate 
staphylococci. S. xylosus (140) and Staphylococcus saprophyticus (136) are intrinsically 
resistant to novobiocin, however, other CoNS such as S. epidermidis, S. haemolyticus, and S. 
lugdunensis are susceptible to novobiocin (140). 
The bacterial membrane consists of a lipid bilayer composed of layers with 
asymmetrically placed lipids (97). The lipid composition in the staphylococcal membrane is 
found to differ during various phases of growth (12, (122, 141), permitting membrane 
adaptability in response to environmental, host defense-related, and antimicrobial stresses. S. 
aureus membrane is compromised of several phospholipids including, phosphatidic acid, 
lysyl-phosphatidylglycerol, phosphatidylglycerol, cardiolipin, phosphatidylethanolamine and 
phosphatidylglucose (97, 122, 141). These phospholipids, along with the carotenoids and the 
glucolipids, form the chief constituents of the staphylococcal membrane (122). 
Because proper cell function depends on the maintenance of optimal membrane 
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fluidity, staphylococci must adapt to changes within the growth environment by adjusting 
their membrane fluidity (17). Adjustments in membrane fluidity, that are dependent on 
changes in lipid composition, must occur in response to environmental changes in pH, 
pressure, temperature, nutrient availability, xenobiotics, and ion concentrations. In several 
bacterial species, the disruption of the lipid arrangement can result from the introduction of 
unsaturated fatty acids into the lipid bilayer. This, in turn, leads to a subsequent increase in 
membrane fluidity. However, S. aureus does not employ this strategy. In contrast, it utilizes 
anteisobranching of the fatty acids to increase fluidity in response to induced stress, such as 
exposure to high salt concentrations (73), and increases iso-branched fatty acids and 
carotenoids to decrease fluidity. Branched-chain fatty acid production is regulated by 
YycFG: a two-component regulatory system (86). 
 
1.1.3. Clinical Importance of the staphylococci 
S. aureus is a commensal and a pathogen. In humans, the major site of S. aureus 
colonization is the anterior nares. About 20–30% of individuals are persistent carriers of S. 
aureus and 30% are intermittent carriers; conversely, 30% of people resist nasal colonization 
(67, 139).  
S. aureus is the major cause for many hospital- and community-acquired infections 
which can result in severe health consequences (26). Nosocomial S. aureus infections affect 
several parts of the body, including the bloodstream, soft tissues, skin, and lower respiratory 
tracts. It is also responsible for causing severe diseases such as serious deep-seated infections 
(i.e osteomyelitis and endocarditis), scalded skin syndrome, toxic shock syndrome, and 
staphylococcal foodborne diseases (117).    
Staphylococcus epidermidis, a well-characterized CoNS, dwells more permanently on 
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the skin due to its high tolerance to salt, acidic pH, and lipids found on skin (73) compared to 
S. aureus, which is not as persistent on the skin. Numerous staphylococci are also associated 
with disease in humans and animals. Staphylococcus saprophyticus is notorious for causing 
urinary tract infections (112). Indeed, CoNS frequently bind to tissues via hemagglutinin, 
fibronectin, teichoic acids, and autolysins on the skin and mucous membranes (41, 100). 
Staphylococcus anaerobius is a pathogen found in sheep and causes skin abscess, but on rare 
occasion, produces abscesses or sepsis in humans (106). 
CoNS also play a role in bacteremia, infections of the central nervous system, 
endocarditis, urinary tract infection, surgical site infections, and many more. Currently, a 
major difficulty lies upon differentiating clinically significant, pathogenic and contaminating 
isolates of CoNS. 
 
1.1.4. Emergence of Antibiotic Resistant Strains of S. aureus  
β-lactam antibiotics interfere with cell wall synthesis by inactivating the 
transpeptidases responsible for cross-linking peptidoglycan chains in the cell wall. As a 
result, the structure of the cell wall is compromised, hampering cell wall-based metabolism 
and cell division, as well as the function of the cell wall, therefore leading to autolysis (126). 
Prior to the introduction of antibiotics in the 1940s, mortality was a common consequence of 
invasive staphylococcal infections (124). In 1941, when penicillin was introduced clinically, 
mortality due to staphylococcal infections reduced greatly (128). Unexpectedly, in 1942, 
penicillin resistance in staphylococcal infections was reported (113) and by the late 1940s, 
penicillin was commonly used in hospitals and penicillin-resistant strains began to appear in 
the clinical setting, exceeding sensitive strains (12). Penicillin-resistance was due to the 
production of a serine protease, β-lactamase, which hydrolyzes penicillin’s β-lactam ring 
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(81). Since penicillin was no longer an effective means of treatment for most S. aureus 
infections, semisynthetic β-lactamase-resistant penicillins, such as methicillin and oxacillin, 
were generated to treat methicillin-sensitive S. aureus. However, within a few years of its 
usage, methicillin-resistant S. aureus (MRSA) strains began to surface (103). From 1975 to 
1991, hospitals in the United States reported an increase in the proportion of S. aureus strains 
resistant to methicillin. By 1991, 79% of hospitals were reporting MRSA cases (103) and by 
2003, approximately 60% of S. aureus strains isolated from intensive care units were 
methicillin resistant (3). As a result, even until now, MRSAs are a serious concern for public 
health. 
MRSA is unique due to the presence of the staphylococcal cassette chromosome, mec 
(SCCmec); a large mobile genetic element that carries the mecA gene. This gene codes for 
PBP2a, an altered penicillin binding protein, that carries low binding affinity to all β-lactams 
compared to PBP2 found in methicillin sensitive strains (5, 59). Until recently, vancomycin 
has remained an effective treatment against most MRSA infections; however, there is 
growing concern for the potential emergence of vancomycin resistant S. aureus strains. These 
concerns stem from reports of clinical isolates of certain species of coagulase-negative 
staphylococci that developed resistance to vancomycin (116, 118). Furthermore, 
vancomycin-resistant enterococci (VRE) had surfaced and spread in many hospital settings in 
the United States (96).  
Although the persistence and high level of antibiotic resistance of strains in the 
hospital setting have been a serious concern, the rise of community-acquired MRSA (CA-
MRSA) has also become a serious public health issue and a financial burden on the health 
care system. CA-MRSA have been shown to be more virulent and often more lethal 
compared to traditional hospital-acquired MRSA (HA-MRSA), causing severe and often 
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fatal infections in otherwise healthy individuals (38). Indeed, community-acquired strains 
had begun to surface in diverse communities including American Indian and Alaska Natives 
(2, 10), sports teams (46), prisoners (1), and children (62). By 2002, up to 20% of CA-MRSA 
isolates were obtained from healthy individuals in the United States who had no established 
risk factors (40).  
A common factor contributing to the pathogenic success of all CA-MRSA is the 
presence of type IV SCCmec element (24). Relative to other SCCmec elements, the SCCmec 
type IV is smaller in size. Moreover, it has been suggested that this element does not impose 
a fitness cost to the bacteria, in contrast to other SCCmec elements, since growth of strains 
carrying SCCmec type IV is not significantly hampered compared with strains that lack this 
element (20, 28). This may be due to the absence of resistance genes other than PBP2a, 
possibly suggesting in part why CA-MRSA disseminates in the community easily. 
Furthermore, SCCmec type IV was possibly acquired from S. epidermidis (144), illustrating 
the important role of horizontal gene transfer for S. aureus evolution (101). 	  
1.1.4.1. CA-MRSA USA300 
In the United States, the large-scale outbreak caused by the CA-MRSA USA300 is, 
one of the most severe in terms of occurrence and severity of infection (38, 88, 94). Indeed, 
USA300 has become a predominant cause of skin and soft tissue infections in emergency 
room patients in the United States (94). Moreover, USA300 is also an increasingly common 
cause of diseases in hospitals (105). 
The astonishing pandemic success of USA300 and its dominance over other CA-
MRSA clones may, in part, be due to the presence of the type I arginine catabolic mobile 
element (ACME) that aids in its colonization and transmission. In USA300, ACME is a 31-
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kb MGE that is physically linked to SCCmec IV and was likely transferred from S. 
epidermidis (27). This mobile genetic element encodes two main gene clusters: an arginine 
deiminase (arc) and an oligopeptide permease (opp) operon. Arginine deiminase activity, 
which is responsible for ammonia and ATP production, facilitates colonization via energy 
production and neutralization of the acid environment on the skin (27, 28). In addition, this 
aids in the prevention of nitric oxide (NO) production, a key molecule utilized by the human 
innate and adaptive host defenses (92). Oligopeptide permeases are also often key players in 
peptide and essential nutrient uptake by bacterial cells. They may also play a potential role in 
quorum sensing, chemotaxis, cell adhesion, and resistance to antimicrobial peptides (27). 
 
1.1.5. S. aureus virulence factors 
The ability of S. aureus to cause a wide array of diseases and persist within the host is 
primarily due to the extensive arsenal of virulence factors expressed by the bacteria, which 
include both structural and secreted products participating in pathogenesis (summarized in 
Table 1). 
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Table 1. Summary of Staphylococcus aureus virulence factors 
Virulence Factor Gene Function/ Effect 
Accessory gene regulator 
 
Staphylococcal accessory 
regulator 
 
Alpha toxin 
Beta hemolysin 
Delta hemolysin 
Gamma hemolysin 
Panton-Valentine Leukocidin 
Protein A 
Fibronectin binding protein 
Fibrinogen binding protein 
Collagen binding protein 
Coagulase 
Clumping factor 
 
V8 Serine protease 
Staphopain B cysteine protease 
Extracellular proteases 
Staphylokinase 
 
Toxin shock syndrome toxin-1 
Capsule 
Exfoliative toxins 
Staphylococcal enterotoxin 
agr 
 
sarA 
 
 
hla 
hlb 
hld 
hlg 
lukPV 
spa 
fnbAB 
fbp 
cna 
coa 
clfA 
 
sspA 
sspB 
splA-F 
sak 
 
tst 
cap 
etaAB 
ent 
Regulates expression of cell-surface and 
secreted proteins 
Up-regulates adhesion molecules and down-
regulates expression of exo-proteins 
 
Cytolytic pore-forming toxin 
Cytolytic pore-forming toxin 
Heat stable pore-forming toxin 
Cytolytic pore-forming toxin 
Damages leukocyte membranes 
Bind Fc portion of IgG molecules 
Adhesion to host tissues 
Adhesion to host tissues 
Adhesion to collagenous tissues and cartilage 
Activates prothrombin 
Fibronectin binding protein, adhesion to host 
tissues 
Cleaves extracellular proteins 
Cleaves extracellular proteins 
Secreted proteases 
Dissolves fibrin clots 
 
Causes acute systemic illness 
Polysaccharide capsule production 
Cause of staphylococcal scalded skin syndrome 
Superantigen toxins, common cause of food 
poisoning, stable in GI-tract 
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The ability of S. aureus to adhere to plasma and extracellular matrix (ECM) proteins 
deposited on biomaterials contributes to the pathogenesis of device-related infections. S. 
aureus encodes for several specific adhesion molecules that are expressed on the cell surface, 
many of which interact with a number of host proteins, such as collagen, fibrinogen, 
vitronectin, fibronectin and laminin (37), and have been designated MSCRAMMs (microbial 
surface components recognizing adhesive matrix molecules). MSCRAMMs facilitate host 
tissue attachment, initiation of colonization, and dissemination of infection (44). Once an 
infection has been established, S. aureus is capable of secreting toxins that perturb the 
membranes of host cells, such as erythrocytes, leucocytes, and platelets. Cytolytic toxins (i.e. 
α-hemolysin, β-hemolysin, γ-hemolysin, leukocidin, and Panton-Valentine leukocidin (PVL) 
form β-barrel pores in cytoplasmic membranes and facilitate cell content leakage and lysis 
(36). Indeed, many of these toxins (i.e. PVL and α–toxin) are highly expressed in CA-MRSA 
(36). 
S. aureus produces a group of heat- and protease-resistant immune-stimulatory 
proteins. These toxins induce the cross-linking of MHC class II molecules found on antigen-
presenting cells with T-cell receptors, thereby causing substantial cytokine production and 
release, and inducing capillary leakage, epithelial damage and hypotension (11). Moreover, 
the super-antigens are believed to weaken the host’s immune system to allow for the 
propagation and persistence of infection (70). The staphylococcal enterotoxins are 
responsible for staphylococcal foodborne diseases (i.e. gastroenteritis), while TSST-1 is 
responsible for causing toxic shock syndrome (11). Many S. aureus virulence factors, and the 
super-antigen toxins specifically, are usually encoded by mobile genetic elements such as 
pathogenicity islands or prophages (98).  
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1.1.6. Regulation of genes involved in virulence 
The growth and survival of bacteria is dependent on the cell’s ability to adapt to 
environmental changes. The genes coding for virulence factors are tightly regulated and are 
synchronized with their biological cycle. The quorum sensing mechanism in S. aureus is 
responsible for controlling the production of a wide array of virulence factors. During early 
stage of growth in S. aureus, there is an upregulation of genes encoding for surface proteins, 
in contrast to the up-regulation of secreted proteins in late exponential or stationary phase. 
Prior to invasion, S. aureus expresses numerous proteins implicated in adhesion and defense 
against the host’s immune system (protein A, coagulase, fibronectin binding proteins, etc.). 
Once the cells have established an infection in the host, S. aureus produces a series of 
secreted hemolysins, proteases, cytotoxins, and other degradative enzymes, to propagate 
invasion.  
The regulation of virulence factor expression in S. aureus is very complex and falls 
under the control of two major families of global regulators that have been well-
characterized: two-component regulatory systems (TCRS) and the SarA family of proteins. 
The system encoded at the agr (accessory gene regulator) locus encodes a quorum sensing, 
two-component regulatory system that controls synthesis of a regulatory RNA, RNAIII, 
which due to its extensive secondary structure is able to regulate the expression of some 138 
genes at both the transcriptional and translational levels (95, 99). Expression of agr peaks 
during the post-exponential phase of growth and corresponds with an up-regulation of toxin 
production and simultaneous decrease in expression of cell wall associated proteins (16). 
Meanwhile, the sarA locus is a DNA binding protein that binds as a homodimer to the so-
called “Sar box” in the promoter region of its target genes, which include numerous cell-wall 
proteins, including adhesion molecules, and also acts as an activator of agr expression (15). 
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SarA is most highly expressed during exponential phase when the expression of cell adhesion 
molecules is at its highest. Indeed, the interplay between these two systems, alongside several 
other regulators of gene expression, results in S. aureus persistence within the host.  
Although several regulatory systems have been identified as regulating virulence genes (15), 
there is a limited understanding of the ability of S. aureus to sense and respond to the 
nutritional status of the environment. Indeed, there is another protein that is currently 
emerging as a link between environmental nutrient availability and regulation of 
pathogenesis.  
 
1.2. CodY 
CodY, a highly conserved regulatory protein, plays a key role in stationary phase 
adaptation in low-G+C gram-positive bacteria, and is currently emerging as a global 
regulator of virulence in S. aureus (83, 110, 134) as well as in other gram-positive pathogens 
(13, 30, 53, 57, 84, 110). First identified in two nonpathogenic species, Bacillus subtilis and 
Lactococcus lactis (47, 125), CodY is able to sense nutrient availability by directly 
interacting with metabolite effectors. Functional homologs of CodY, define a unique, winged 
helix-turn-helix-containing family of transcription factors. By sensing intracellular levels of 
branched-chain amino acids (BCAAs; isoleucine, leucine, and valine) and/or GTP during 
growth, CodY is able to respond by repressing genes involved in nitrogen metabolism 
(oligopeptide transporters, toxins, proteases, genes involved in amino acid biosynthesis and 
transport) and activating transcription of genes of the carbon overflow pathway (47, 121). As 
a result, by interacting with BCAAs and GTP, CodY is able to sense both carbon and 
nitrogen availability, and is also linked with the stringent response. Moreover, the regions of 
B. subtilis CodY predicted to be important for DNA binding (61, 77) and for BCAA 
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interaction (22, (138) are highly conserved in CodY proteins from many species, including S. 
aureus (77). 
For B. subtilis, Clostridium difficile, Listeria monocytogenes, Bacillus cereus, and S. 
aureus CodY, the effectors are GTP and the BCAAs (13, 30, 57, 91, 114, 121). GTP and the 
BCAAs act independently and synergistically to increase CodY affinity for its DNA target 
sites (49, 138). In contrast, L. lactis and Streptococcus pneumoniae CodY proteins respond 
solely to BCAAs (53, 109). In S. aureus, abundance of BCAAs and GTP yields high CodY 
activity in rapidly growing cells. As intracellular BCAA and GTP pools decline, CodY loses 
its affinity for its DNA target sites, bringing about de-repression of its target genes (129). 
This allows the cells to transition from growth and division to amino acid metabolism and 
stress tolerance, highlighting the central role of CodY in gram-positive metabolic regulation 
and virulence.  
 
1.2.1. Effectors of CodY 
BCAAs stimulate conformation change by binding to the N-terminal GAF domain of 
CodY, and this is thought to increase the affinity of CodY for its DNA target sites (25, 76, 
77). In L. lactis, a study was conducted to investigate which BCAA(s) is/are needed for 
CodY activity (48). Indeed, CodY binding was significantly enhanced with the presence of 
isoleucine, however, both leucine and valine had a negligible effect in DNA binding (48). In 
S. aureus, isoleucine also appeared to be the major cofactor for CodY (110). Moreover, 
growth inhibition was a direct result of excess isoleucine, due to abnormal activation of 
CodY. This may be due to blockage of metabolic pathways involved in amino acid synthesis 
(48). On the other hand, valine was also able to bind to B. subtilis CodY, and had a 18-fold 
higher affinity for DNA (77). 
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Similar to BCAAs, there is a decline in intracellular GTP levels when bacteria enter 
stationary phase of growth and are exposed to nutrient limited environments. For example, 
the intracellular GTP concentration in B. subtilis is predicted to range from 2 to 3 mM during 
the exponential phase of growth, and drops to approximately 300 uM during the early-
stationary phase (49, 127). By binding GTP, CodY is able to directly sense the cell’s 
energetic status and may control the expression of several genes responsible for 
morphological differentiation and development. The binding site of GTP in the CodY protein 
remains unclear, but it is certainly not located in the GAF domain (49, 76, 77). Lastly, the 
difference in gene repression by BCAA-CodY or GTP-CodY is not yet elucidated. 
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A. 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. A) Genetic scheme of codY operon consisting of genes hslV and hslU encoding 
heat shock proteins, and a tyrosine recombinase, xerC. B) BCAAs and GTP act as effector 
molecules and play a role in regulating the function of CodY in S. aureus 
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1.2.2. CodY regulation on global regulators 
S. aureus CodY appears to regulate two major global regulatory systems, agr and 
sarA, demonstrating that numerous connections and interactions take place between these 
regulatory proteins (83). CodY directly represses both sarA and agr systems as demonstrated 
by various studies (82, 83, 110). Moreover, deletion of codY in S. aureus strains SA564 and 
UAMS-1 led to de-repression of mRNA levels for various toxins, such as α-toxin (hla) and 
δ-toxin (hld), as well as the accessory gene regulator (agr) (RNAII and RNAIII) (83). As a 
result, it was shown that the culture supernatant of a S. aureus codY mutant displayed greater 
hemolytic activity towards rabbit erythrocytes compared to the wild type strain (83). This 
suggests that CodY indirectly represses hemolytic activity by repressing the agr system 
during the exponential growth phase. Interestingly, the de-repression of the CodY regulon 
and the activation of the Agr system simultaneously occur when cells enter the stationary 
phase. Indeed, in nutrient depleted environments, CodY target genes are de-repressed 
whereas the Agr system is induced by the high concentration of bacteria (quorum-sensing 
effect). Under limited isoleucine conditions, the agr is prematurely activated due to de-
repression of CodY, possibly permitting the bacteria to escape and increasing virulence under 
nutrient limiting conditions (110). The agr system of S. aureus does not influence the 
transcript levels of CodY (110). 
  
1.3. Metabolism 
1.3.1. Amino acid requirements for staphylococcal growth  
The metabolic regulatory cascades for staphylococci are unconventional and unclear, 
and there is a limited understanding on the link between nitrogen metabolism and amino acid 
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availability during infection. However, there is increasing evidence that CodY plays a central 
role as a regulator that links both metabolism and virulence gene expression in pathogenic 
bacteria (13, 30, 53, 114). 
Most species of staphylococci require a complex mixture of nutrients; however, in 
general, they require an organic source of nitrogen, supplied by 5 to 12 essential amino acids, 
e.g. arginine, valine, and B vitamins, including thiamine and nicotinamide (66, 142). Various 
phenotypic studies that have looked at S. aureus nutritional requirements have attempted to 
determine the amino acids needed for growth (35). It was revealed that S. aureus often had 
numerous amino acid auxotrophies; however, it was also observed that these auxotrophies 
would revert back to a prototrophic state quite frequently. This suggested that absence, or 
genetic inactivation of biosynthetic pathways were not responsible for the auxotrophies (35, 
42), but that feedback inhibition of the biosynthetic enzymes or repression of synthesis in 
corresponding pathways may be the likely cause (52). Whole genome sequencing of S. 
aureus was performed to confirm this, and it was determined that, indeed, biosynthetic 
pathways exist for all amino acids (8, 27, 72). Nevertheless, because a complex mixture of 
amino acids are required for optimal S. aureus growth, it has been suggested that bacteria 
have evolved the ability to acquire at least some of the amino acids from the host. Genes 
coding for oligopeptide transporters were also identified in a whole-genome screen, and were 
shown to be activated and necessary for infection (22, 87). The S. aureus genome also 
consists of genes encoding for proteases, whose activity could play a role in facilitating 
amino acid or peptide uptake during infection. 
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1.3.2. Branched-chain amino acids 
Branched-chain amino acids provide an essential source of nitrogen for virtually all 
living organisms. The three branched-chain amino acids (BCAAs), leucine, isoleucine, and 
valine, are the most hydrophobic of the amino acids and are involved in determining the 
structures of several globular proteins. Moreover, these amino acids are precursors for the 
biosynthesis of iso- and anteiso-branched fatty acids, which are the dominant major fatty 
acids in the membrane (23). The interior of water-soluble globular proteins is primarily 
composed of hydrophobic amino acids, leucine, isoleucine, valine, phenylalanine, and 
methionine. This contributes to protein stability during the folding process, and also for the 
folding pathway that leads to the mature form (29). The hydrophobic residues are involved in 
the processes of some biologically essential globular proteins, such as the binding of oxygen 
in myoglobin and hemoglobin, and for substrate binding and catalysis in a variety of 
enzymes (18). Despite their similarity, the three BCAAs play slightly different roles in 
proteins. Regardless of this similarity, the differences in the properties of their side-chains, 
(i.e size, shape, and hydrophobicity), allows them to have unique preferences for various 
secondary structure motifs. Leucine is more commonly found in α-helices than in β-sheets, 
whereas both valine and isoleucine have a preference for the opposite (19). 
In humans, 35–40% of the dietary essential amino acids in body protein and 14–18% 
of the total amino acids in muscle proteins are composed of BCAAs (75, 115). The muscle 
mass of humans is ∼40% of the body weight; therefore, a large reservoir of BCAAs can be 
found in muscle protein. However, in human blood, the total concentration of free BCAAs is 
approximately ranges from 0.3 and 0.4 mM and is relatively small compared with that found 
in muscle proteins. As a result, bacteria have evolved various strategies in order to scavenge 
free BCAAs from the host to obtain these essential nutrients from the host.  
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1.3.3. Biosynthesis of BCAAs 
The pathways for BCAA biosynthesis have mostly been studied in E. coli and S. 
typhimurium and to lesser degrees in Neurospora crassa and yeast. Many of these studies 
have experienced complications due to the antagonism that occurs between the three BCAAs. 
Since the time that it was first reported by Gladstone (43) in 1939 with Bacillus anthracis, 
additional examples have been reported in which antagonism occurs between two or three 
branched-chain amino acids at various points in metabolism. Such interactions are not 
surprising, since the three branched-chain amino acids (and their precursors) are analogs of 
each other. The kinds of antagonism that have been seen include interference with active 
transport into the cell, end-product control, repression control, and, potentially with 
incorporation into protein (135). The biosynthesis pathway for each BCAA is outlined in 
Figure 3.  
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Figure 2. Structure of branched-chain amino acids valine, leucine and isoleucine, each 
having aliphatic side-chains with a branch (a carbon atom bound to more than two other 
carbon atoms). 
 
 
 
 
 
 
 
 
 
21	  
	  
	  	  	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Biosynthesis pathway for branched-chain amino acids in S. aureus. Note that 
isoleucine is synthesized from threonine. 
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1.4. Preface to bacterial BCAA uptake 
Environmental nutrient acquisition by bacteria is essential for survival and 
persistence. Growth and division stop when cells are exposed to nutrient limitation, causing 
the population size to remain stationary. A hallmark of this transition is a decline in 
intracellular BCAA levels (39, 49, 80, 89, 133). Despite the fact that BCAA levels are 
restricted within the host, pathogenic bacteria still manage to survive, and in some cases, 
thrive even though the amount of free BCAAs available to them is limited or difficult to 
obtain. Indeed, bacterial survival is dependent upon the development of specialized BCAA 
uptake systems that allow them to over-come BCAA withhold strategies of the host to meet 
their nutritional needs.  
 
1.4.1. ATP-binding cassette (ABC) transporters 
In bacteria, ATP-dependent active transport can allow molecules to enter the cell. 
This mechanism of transport involves the utilization of energy from hydrolysis of ATP to 
circumvent the electrochemical gradient and facilitate transport of solutes. ATP-dependent 
translocation occurs via transporters that belong to the ATP-binding cassette (ABC) 
transporter superfamily. The general structure of ABC transporters includes a membrane 
channel formed by two proteins containing transmembrane domains, and two cytoplasmic 
modules that bind and hydrolyze ATP to drive solute transport. In S. aureus, ABC 
transporters have been implicated in the transportation of various solutes including metal ions 
(78), heme (123), and oligopeptides (54) and are also predicted to transport polyamines, 
maltose, and amino acids (102). 
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1.4.2. BCAA uptake systems in bacteria 
Many genes involved in transport of BCAAs have been identified by way of full 
genome sequencing. E. coli consists of two different transport systems responsible for BCAA 
uptake, both of which are high-affinity ABC transporters: LivFGHMJ and LivFGHMK (58). 
Among them, all three BCAAs bind to LivJ, while only L-leucine binds to LivK (58). The 
low-affinity BCAA transporter, BrnQ, functions as a Na+/BCAA symporter (4). While LivK 
is specific for L-leucine transport, BrnQ is involved in the uptake of other BCAAs as well as 
L-leucine. Thus, it was suggested that the complete knockout of brnQ and livK might cause 
growth retardation due to L-leucine and L-isoleucine deficiency (104). In C. glutamicum, 
BrnQ also mediates Na+/- dependent import of all three BCAAs (34). In L. lactis, BcaP, the 
branched-chain amino acid permease, is the major BCAA transporter. Deletion of bcaP, 
along with brnQ, a second low-affinity BCAA permease, resulted in reduced viability of the 
strain due to inability to take up BCAAs (25).   
 
 
 
 
 
 
 
 
 
 
 
24	  
	  
1.5. Research Objectives 
 The goal of this research was to study the branched-chain amino acid uptake systems in 
S. aureus. We hypothesize that BrnQ transporters are involved in BCAA uptake and 
contribute to virulence in S. aureus by modulating CodY activity. The first objective was to 
identify putative branched-chain amino acid transporters in S. aureus USA300 using BLAST 
analysis and sequence similarity. The second objective was to generate mutations of each 
branched-chain amino acid transport system to facilitate study of each transporter. Thirdly, a 
combination of radioactive uptake assays and growth experiments were used to characterize 
the role of the branched-chain amino acid transporters in S. aureus. The final objective of this 
research was to determine the role of the branched-chain amino acid transporters on S. 
aureus virulence in vivo using a mouse model of bacteremia. The central focus of the 
research is directed towards understanding the mechanisms and modulators of adaptation and 
survival of S. aureus in nutrient-limited environments.  
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2.1. Bacterial strains and growth conditions 
The bacterial strains and plasmids used in this study are described in Table 2. MRSA 
isolate pulsed-field gel electrophoresis type USA300 LAC that had been cured of the 
erythromycin resistance plasmid was used in all experiments as the wild type (WT) strain. 
Unless otherwise indicated, both E. coli and S. aureus were cultured at 37°C and stored at -
80 °C in 15% glycerol. E. coli strains were grown in Luria Bertani (LB) medium. S. aureus 
strains were grown either in tryptic soy broth (TSB) or in a chemically-defined medium 
(CDM). For strains carrying resistance genes, antibiotics were used at the following 
concentrations: chloramphenicol (10μg/mL) and tetracycline (4μg/mL) for growth of S. 
aureus strains; ampicillin (100μg/mL) for growth of E. coli strains. Complete CDM was 
composed as follows (final concentrations in uM): amino acids from a 10X stock; alanine 
(672), arginine (287), aspartic acid (684), cysteine (166), glutamic acid (680), glycine (670), 
histidine (129), isoleucine (228), leucine (684), lysine (342), methionine (20), phenylalanine 
(240), proline (690), serine (285) threonine (260), tryptophan (50), tyrosine (275), valine 
(684); vitamins and metal ions from a 1000X stock (final concentrations in uM); thiamine 
(56), nicotinic acid (10), biotin (0.04), pantothenic acid (2.3), MgCl2 (1000), CaCl2 (100); 
salts from a 10X stock; monopotassium phosphate (40000), dipotassium phosphate (14700), 
sodium citrate dihydrate (1400), magnesium sulphate (400), ammonium sulphate (7600); 
carbon source; glucose (27753). The concentrations of individual amino acids were modified 
in some experiments, as indicated in the Results and Figure legends. The pH of the medium 
was buffered to 7.0. Solid media were obtained by the addition of 1.5% (w/v) Bacto agar 
(Difco). Water for preparation of growth media and solutions was obtained by passage 
through a Milli-Q water filtration system (Millipore Corp.). 
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Table 2. Bacterial strains used in this study 
Strain or plasmid Descriptiona Source or 
reference 
 
Strains 
 
S. aureus 
 
  
USA300 LAC Community-acquired MRSA; WT strain (88) 
USA300 USA300 LAC cured of antibiotic resistance plasmid (6) 
RN4220 rK- mK+ ; capable of accepting foreign DNA (71) 
RN6390 Prophage-cured laboratory strain (108) 
Newman WT clinical isolate (33) 
H2324 Newman ΔbrnQ3::Tet; TetR This study 
H2568 USA300 ΔbrnQ1 (SAUSA300_0188) This study 
H2563 USA300 ΔbrnQ2 (SAUSA300_0306) This study 
H2578 USA300 ΔbrnQ3::Tet; TetR (SAUSA300_1300) This study 
H2586 USA300 ΔbrnQ1 ΔbrnQ2 This study 
H2580 USA300 ΔbrnQ1 ΔbrnQ3::Tet; TetR This study 
H2581 USA300 ΔbrnQ2 ΔbrnQ3::Tet; TetR This study 
H2589 USA300 ΔbrnQ1 ΔbrnQ2 ΔbrnQ3::Tet; TetR This study 
   
E.coli 
 
  
DH5α F- ϕ80dlacZΔM15 recA1 endA1 gyrA96 thi-1 
hsdR17 (rK− mK-) supE44 relA1 deoR Δ(lacZYA-
argF)U169phoA 
 
Promega 
 
 
 
a Abbreviations: Cmr, Apr, Tetr designate resistance to chloramphenicol, ampicillin, and 
tetracycline, respectively 
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2.2. DNA Methodology 
 
2.2.1. Plasmid isolation from E. coli 
All plasmids used in this study are listed in Table 3. Plasmid DNA was prepared from 
E. coli using the E.Z.N.A. Plasmid Miniprep Kit (Omega Biotek) according to the 
manufacturer’s index. In summary, approximately 5 mL of stationary phase culture of E. coli 
were pelleted via centrifugation and resuspended in 250 μL of SolutionI/RNase (50mM Tris, 
pH 8.0, 20 mM EDTA, 100μg/mL of RNaseA). Cells were lysed by adding 250 μL of 
Solution II (200 mM NaOH, 1% (w/v) SDS) and gently inverting the tubes and incubating 
the cells at room temperature for 2-5 minutes. To neutralize the solution, 350 μL of Solution 
III (guanidine hydrochloride with acetic acid) was added to the lysate and was immediately 
inverted several times until a precipitate formed. The insoluble material was subsequently 
centrifuged for 10 minutes at 13000 ✕ g to form a pellet. The resulting cleared supernatant 
was aspirated into a HiBind DNA Miniprep Column (I) and was centrifuged at 13000 ✕ g for 
1 minute. 500 μL of Buffer HB was added to wash the column and ensure that residual 
protein contaminations are removed. 700 μL of DNA Wash Buffer diluted with absolute 
ethanol was added to the column and centrifuged for 1 min at 13000 ✕ g. The column was 
subsequently centrifuged for 2 minutes at 13000 ✕ g to dry the column matrix. Plasmid DNA 
was then eluted from the column into a fresh microcentrifuge tube by addition of 30 μL to 
100 μL of dH2O followed by centrifugation at 13000 ✕ g for 1 minute.  
 
2.2.2. Plasmid isolation from S. aureus 
Plasmid DNA isolation from S. aureus essentially followed the same protocol as 
described above for E. coli but with slight modification. Bacterial cells that were harvested 
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were incubated at 37 °C for 30-60 minutes in a 250 μL mixture of Solution I containing 
lysostaphin (Sigma) (1 mL Solution I added to 50 μg of lysostaphin) in lieu of RNase A 
solution, prior to addition of Solution II. 
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Table 3. Plasmids used in this study 
Plasmid Descriptiona Source or 
Reference 
pRMC2 Anhydrotetracycline-inducible expression vector; Apr in E. 
coli; Cmr in S. aureus 
(21) 
 
pSO1 pRMC2 containing brnQ1; CmR This study 
pSO2 pRMC2 containing brnQ2; CmR This study 
pSO3 pRMC2 containing brnQ3; CmR This study 
 
a Abbreviations: Cmr and Apr designate resistance to chloramphenicol and ampicillin, 
respectively. 
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2.2.3. Isolation of chromosomal DNA from S. aureus 
Chromosomal DNA was obtained from S. aureus by pelleting 500 μl of overnight 
stationary phase cells grown in TSB culture. 200 μl of STE (75 mM NaCl, 25 mM EDTA, 20 
mM Tris pH 7.5) was added to the cells along with 50 ug/ml of lysostaphin dissolved in 20 
μL of STE in order to facilitate cell lysis. The cell suspension was incubated at 37 °C for 1 
hour. 20 μl of 10% SDS and 20 μL of Proteinase K (New England Biolab) were added and 
incubated overnight at 55 °C. Subsequently, 80 μl of 5M NaCl was added and mixed by 
inversion. 320 μl of a 25:24:1 phenol : chloroform : isoamyl alcohol (Invitrogen) was added 
and was allowed to sit at room temperature for 30 minutes. The aqueous layer was removed 
after the mixture was spun at 12000 ✕ g for 10 minutes. Addition of 300 μl of 24:1 
chloroform : IAA was added and then spun at 12000 ✕ g for 10 minutes. The aqueous layer 
was subsequently removed, and 400 μl of isopropanol was adding until the DNA formed a 
visible mass with gentle inversion. The mixture was allowed to sit for 10 minutes at room 
temperature, and was then spun at 12000 ✕ g for 5 minutes. The pellet washed with 70% 
ethanol, dried, and resuspended in 100 μl of dH20.  
 
2.2.4. Restriction Enzyme Digests 
Restriction enzymes were purchased from Life Technologies, MBI Fermentas, New 
England Biolabs, or Roche Diagnostics. Reactions were typically carried out in 30-40 μl 
volumes over a 1-2 hour incubation at the appropriate temperature (typically 37 °C). 
Digested DNA was subsequently cleaned using a QIAquick PCR purification kit (QIAgen) as 
described by the manufacturer.   
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2.2.5. DNA ligation 
DNA fragments were generally ligated in a 20 μl reaction volume using a 10:1 ratio 
of insert to vector DNA. Reactions were carried out using the T4 DNA ligase Rapid Ligation 
Kit (Roche Diagnostics) in accordance with the manufacturer’s instructions. 
 
2.2.6. Agarose gel electrophoresis 
 Agarose gel electrophoresis was used for the separation and analysis of DNA 
fragments. Agarose gels (0.8% w/v) were prepared using 1X TAE buffer (40 mM Tris 
acetate, 1 mM EDTA) to which either 1.5 ug/ml of ethidium bromide or 2 μl of SYBR Safe 
DNA gel stain (Invitrogen) was added. DNA samples to be run were mixed with loading 
buffer (5% glycerol, 0.04% bromophenol blue, 0.04% xylene cyanol, 10 mM EDTA, pH 7.5) 
prior to being loaded in the gel. Electrophoresis was typically carried out at 110 V for 20-25 
minutes. The 1 kb-Plus ladder (Invitrogen) was used as a standard reference marker for 
estimation of DNA fragment size. Following electrophoresis, DNA fragments were 
visualized using a gel doc (Bio-Rad).  
 
2.2.7. Isolation of DNA fragments from agarose gels 
DNA fragments were visualized under long wave UV light (365 nm) and excised 
from agarose gels following electrophoresis. DNA was isolated using the QIAquick Gel 
Extraction Kit (QIAGEN) using a protocol as described by the manufacturer.  
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2.2.8. Polymerase chain reaction (PCR) 
 PCR reactions were carried out in 50 μl reactions containing: DNA template, 1x PCR 
buffer, 200 μM dNTP mix (Roche Diagnostics), 12 pM of forward and reverse primers, and 
0.5 units of Taq DNA polymerase. PCR reactions were also carried using KAPA HiFi 
HotStart PCR Kits (Kapa Biosystems). Briefly, 25 μl reactions containing template DNA, 1X 
Kapa HF Buffer (2.0 mM Mg 2+ at 1X), 300 μM of dNTPs, 300 nM each of forward and 
reverse primer and 0.5 units of KAPA HiFI HotStart DNA Polymerase. PCRs were 
performed using the GeneAmp PCR system (Perkin Elmer), DNA engine Gradient Cycler 
(Bio-rad) or the MJ Mini Personal Thermal Cycler (Bio-rad). Oligonucleotide primers were 
obtained from Integrated DNA technologies.  
 
2.2.9. DNA sequencing 
DNA sequencing was performed at the DNA Sequencing Facility of the Robarts 
Research Institute (London, Ontario, Canada), with sequencing reactions prepared according 
to their guidelines.  
 
2.2.10. Computer Analyses 
DNA sequence analysis, sequence alignments, and oligonucleotides primer design 
were carried out using Vector NTI Suite 7 software package (Informax, Inc., Bethesda, 
Maryland). Blast searches were performed using tools available through the National Center 
for Biotechnology Information (http://www.ncbi.nlm.nih.gob/blast/). 
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2.3. Transformation and transduction methodologies 
2.3.1. Preparation of transformation competent E. coli 
E. coli DH5α CaCl2 competent cells were prepared as follows. An overnight, 
stationary phase culture of DH5α was diluted 1:100 into 500 ml of fresh LB and grown to an 
OD600 of approximately 0.5 and placed on ice for 30 minutes. The cells were then harvested 
via centrifugation and resuspended in 100 ml of ice-cold 100 mM CaCl2 plus 15% glycerol 
and incubated on ice for 30 minutes. Cells were again collected by centrifugation, 
resuspended in 4 ml of CaCl2 plus 15% glycerol, and stored as 100 μl aliquots at -80 °C.  
 
2.3.2. Transformation of CaCl2  competent E. coli 
To transform CaCl2 competent E. coli DH5α, purified plasmid DNA, PCR product, or 
ligation mixtures were added to an aliquot of competent cells and kept on ice for 45 minutes, 
after which cells were subjected to a heat shock treatment at 42 °C for 2 minutes immediately 
followed by a 2 minute incubation on ice. An 800 μl aliquot of LB broth was added to the 
tube, mixed, and the cells were permitted to recover for 1 hour at 37°C before being plated 
on selective media and incubated overnight. 
 
2.3.3. Preparation of transformation competent S. aureus 
Strains of S. aureus were made competent for transformation via electroporation as 
follows. An overnight culture of S. aureus was diluted 1:100 into 100 mL of fresh TSB and 
grown to an OD600 of approximated 0.3. Cells were then harvested via centrifugation and 
resuspended in 500 mM sucrose. Cells were subsequently washed three times with ice cold 
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500 mM sucrose. After the final wash, cells were resuspended in 1 mL of 500 mM sucrose 
and stored as 80 μl aliquots at -80°C.  
 
2.3.4. Transformation of electrocompetent S. aureus  
Electrocompetent S. aureus were transformed using purified plasmid DNA (typically 
5 μl from an EZNA miniprep). DNA was added to a tube of competent cells and allowed to 
incubate on ice for 30 minutes before being transferred to an ice-cold electroporation cuvette 
(2mm, Bio-Rad) for electroporation. Following incubation, electroporation was performed 
using a Bio-Rad Gene Pulser II with setting of 2.5 V, 200 mA, and 25 Ω. Ice cold TSB (800 
μl) was immediately added to pulsed cells, which were then recovered for a minimum of 1 
hour at 37°C before being plated on appropriate selective media.  
 
2.3.5. Preparation of phage lysate of S. aureus 
Bacteriophage 80α was recovered from S. aureus RN2564 by UV induction as 
previously described (119). For routine preparation of infective lysates, 500 μl of an 
overnight culture of S. aureus was diluted 1:1 in fresh TSB supplemented with 2.5 mM CaCl2 
and incubated at 37°C for 10 minutes. Subsequently, 100 μl of various dilutions of phage 
80α were added. This mixture was allowed to incubate for an additional 15 minutes at 37°C 
before being added to 20 ml of TSB with 2.5 mM CaCl2 and incubated with slow shaking at 
37°C until lysis of culture was observed. Following lysis, cell debris was removed via 
centrifugation at 6000 ✕ g for 10 minutes and the phage lysate was sterilized by passage 
through a 0.45 μm filter (Millipore). All phage lysates were maintained at 4°C.  
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2.3.6. Transduction of S. aureus 
Transduction of S. aureus strains was performed as follows. A 5 ml culture of the 
recipient strain was grown in TSB with 2.5 mM CaCl2 to an OD600 of 0.9, at which time, 1 ml 
of culture was harvested by centrifugation and resuspended in 500 μl of fresh TSB. This was 
further divided into 100 μl aliquots. Various dilutions of phage 80α lysates were added to 
each aliquot and incubated for 20 minutes at 37°C. This was followed by the addition of 10 
μl of 1 M sodium citrate to halt the phage infection. Cells were then exposed to 1/50th the 
selective concentration of the appropriate antibiotic for 1 hour at 37°C before being plated on 
appropriate selective media.  
 
2.4. Mutagenesis and DNA cloning methods 
2.4.1. Mutagenesis of brnQ 
Deletions of brnQ1 and brnQ2 genes were constructed using the pKOR-1 plasmid as 
described previously (9). Primer sequences were based on the published USA300 FPR3757 
and are displayed in Table 4 (27). Briefly, sequences flanking the brnQ locus were PCR 
amplified with primers for the upstream fragment and primers for the downstream fragment. 
A PCR amplicon of the joined DNA fragments was recombined into the temperature-
sensitive vector pKOR1 using BP clonase reaction (Invitrogen), resulting in the pKOR-
1ΔbrnQ1 and pKOR-1ΔbrnQ2 plasmids. The resulting plasmids were first passed through S. 
aureus RN4220, before electroporation into strain USA300. Precise in-frame allelic 
replacement of the brnQ genes was established by a two-step process of temperature shifting 
and antisense counter-selection (9) and confirmed by PCR and sequence analysis. The 
brnQ3::Tet knockout allele consisted of a  tetracycline resistance cassette, excised from 
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plasmid pDG1513 with restriction enzyme PstI, flanked by DNA sequences homologous to 
regions upstream and downstream of brnQ3 – leaving the first 69 bp of the start of the gene 
and the last 34 bp of the gene. The knockout allele was cloned into the temperature-sensitive 
E. coli/ S. aureus shuttle vector pMAD, and then passaged through S. aureus RN4220 at 
permissive temperatures prior to being transduced into S. aureus RN6390. Recombinant 
RN6390 was cultured at 30 ˚C to mid-log phase before the incubation temperature was 
shifted to 42 ˚C. The bacteria were further incubated for 16 hours before being plated onto 
TSA containing tetracycline. Colonies were screened for sensitivity to erythromycin, which 
indicates loss of the pMAD backbone DNA after integration of the knockout allele into the S. 
aureus chromosome via double homologous recombination. The ΔbrnQ3::Tet deletion was 
confirmed by PCR and mobilized to S. aureus  USA300 by transduction using phage 80α as 
described above. 
 
2.4.2. Construction of vectors to complement a brnQ mutant 
 Each of the brnQ genes, including their endogenous promoters, was cloned into the 
shuttle vector pRMC2 (21). Primers and restriction enzymes used are outlined in Table 4.  As 
listed in Table 3, the resultant plasmids encoding brnQ1, brnQ2 and brnQ3 were designated 
pSO1, pSO2, and pSO3, respectively. 
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Table 4. Oligonucleotide primers used for mutagenesis and cloning 
Oligonucleotidesa  
 
brnQ1 5’F 
 
brnQ1 5’R 
 
 
brnQ1 3’F 
brnQ1 3’R 
 
 
 
brnQ2 5’F 
 
brnQ2 5’R 
 
 
brnQ2 3’F- 
brnQ2 3’R- 
 
 
 
brnQ3 5’F- SalI 
brnQ3 5’R- PstI 
 
 
brnQ3 3’F- PstI 
brnQ3 3’R- SmaI 
 
 
brnQ1SA5’F-KpnI 
brnQ1SA3’R-SacI 
 
 
brnQ2SA5’F-KpnI 
brnQ2SA3’F-SacI 
 
 
brnQ3SA5’F-KpnI 
brnQ3SA3’F-SacI 
 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGACCT 
GCAAGAAGGTATTC 
GGGCGTAAGTTAAGAACGA 
Generation of 5’ arm for deletion of S. aureus brnQ1 
 
/5Phos/AAGGAGGGAGACCGATGAAT 
GGGGACCACTTTGTACAAGAAAGCTGGGTTGGCTAAA 
GGGTTACCACCA 
Generation of 3’ arm for deletion of S. aureus brnQ1 
 
GGGGACAAGTTTGTACAAAAAAGCAGGCTGCGCCAT 
AGACAGGTTTAGC 
TGGAAATACGTTGGAGCGTTG 
Generation of 5’ arm for deletion of S. aureus brnQ2  
 
/5Phos/ACCCATCGTTACTAGGCTTT 
GGGGACCACTTTGTACAAGAAAGCTGGGTTAAAAGC 
CGCAGCGATATTC 
Generation of 3’ arm for deletion of S. aureus brnQ2 
 
TTGTCGACGATTGAACGAGAACAACGAGATGC  
TTCTGCAGGCGTAAACCCAATGACCCATG  
Generation of 5’ arm for generation of S. aureus brnQ3::Tet allele 
 
TTCTGCAGCAACGATATTAGGCTATCTAGTCGGC 
TTCCCGGGAGCTCGTTGAGCTGCTATTTTCC  
Generation of 5’ arm for generation of S. aureus brnQ3::Tet allele  
 
GATCGGTACCGTTCTTAACTTACGCCC  
GATCGAGCTCCAGTTGTTCAATATAAG 
Cloning of S. aureus brnQ1 
 
GATCGGTACCTTTCCAACTTACTTTCA 
GATCGAGCTCTCAATAGACAGACGGT 
Cloning of S. aureus brnQ2 
 
GATCGGTACCCATGTGTTTTGTTTCTG 
GATCGAGCTCTAATGGCGAGACTCCT 
Cloning of S. aureus brnQ3 
 
a Restriction sites in sequences are underlined 
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2.5. Radioactive transport assays 
Cultures were grown overnight at 37°C in complete CDM and subcultured into 5 ml 
of complete CDM at a starting OD600 of 0.1. Bacteria were grown to mid-log phase (OD600 of 
1.0), cells were washed and resuspended in CDM without amino acids. Cells were harvested 
by filtration on 0.45-μm pore-size membrane filters and washed with saline before being 
resuspended in CDM lacking amino acids.  Cells were then shaken at 200 rpm at 37°C for 10 
minutes prior to the assay. For the uptake assay, 10 μL of a mixture containing 15 mM of an 
unlabeled amino acid of interest and 0.05 μCi of amino acid in 14C-labeled form (Perkin 
Elmer, MA) were added to 1 mL of culture to initiate transport. 200 μL were aliquoted at 
indicated time intervals and rapidly filtered through 0.45-μm membrane filters. The filters 
were immediately washed with 20 mL of 0.1 M LiCl2 at room temperature. Filters were dried 
and placed in scintillation vials containing 4 mL of scintillation fluid. Radioactivity was 
measured using the tritium channel of a scintillation system LS 6500 (Beckman). Variations 
to mixtures and amino acids are as described in the text and figure legends. 
 
2.6. S. aureus growth curves 
Strains of S. aureus to be tested were pre-grown overnight in either TSB or complete 
CDM. Cells washed and sub-cultured into the same medium or into CDM with decreased 
concentration of branched-chain amino acids (as outlined in figure legends) to a starting 
OD600 equivalent of 0.0025. Bacterial growth was monitored by measuring the optical density 
of the culture at 600 nm until stationary phase was reached.  
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2.7. Murine Systemic Model of S. aureus Infection 
All protocols were reviewed and approved by the University of Western Ontario's 
Animal Use Subcommittee, a subcommittee of the University Council on Animal Care. 
Seven-week-old female immunocompetent BALB/c mice were purchased from Charles 
River Laboratories (Wilmington, MA) and housed in microisolator cages. Bacteria were 
grown to mid-log phase (OD600 of approximately 1.0-3.0) in TSB, pelleted by centrifugation, 
washed twice in PBS, and resuspended in phosphate-buffered saline. Bacterial suspensions in 
100-μL volumes were administered via tail vein (6-7 × 106 CFU). Ninety-six hours post-
challenge, kidneys, livers, and hearts were excised and placed in a phosphate-buffered 
solution containing 0.1% (vol/vol) Triton X-100. Organs were homogenized for 10 s, and 
bacterial loads were calculated following serial dilution of the suspension and drop plating on 
TSB agar plates. Data are presented as log10 CFU recovered per organ or organ pair in the 
case of kidneys. Data were analyzed using the Student’s unpaired t-test and P values of <0.05 
were considered to indicate statistical significance.	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Chapter 3- Results 
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3.1. Identification of putative branched-chain amino acid uptake 
transporters 
 
A S. aureus N315 braB mutant was previously identified through signature tagged 
mutagenesis (STM) as being attenuated in a mouse model of systemic infection (14). BLAST 
analysis demonstrates that this protein was allelic with USA300 S. aureus gene brnQ3, 
encoding a 447-amino-acid branched-chain amino acid carrier protein and 100% amino acid 
identity to BraB. BLAST searches of the databases show that the USA300 gene product 
exhibits 34% identity and 56% total similarity to the BrnQ proteins of Salmonella enterica 
sv. Typhimurium and E. coli, 34% identity and 54% total similarity to the BrnQ protein of 
Corynebacterium glutamicum, and 35% identity and 55% total similarity to the BraB protein 
in Pseudomonas aeruginosa. BrnQ and BraB proteins are involved in the Na(+)- coupled 
import of branched chain amino acids (BCAAs) (46, 56, 130). Hydropathy profiles indicate 
that the proteins are likely to contain 12 membrane-spanning domains. The gene has been 
annotated in the S. aureus COL genome as brnQ3 since there are two additional brnQ 
paralogs in S. aureus. Pairwise alignments demonstrate that the three BrnQ paralogs share 
approximately 30-35% identity and 50-55% total similarity across the total length of the 
proteins. The S. aureus, brnQ3 gene was previously identified in screens for salt-sensitive 
mutants (137), but its function, as well as that of brnQ1 and brnQ2 as branched-chain amino 
acid carrier proteins have not been formally tested. BrnQ1 in USA300 shares 61% identity 
and 78% total similarity with the BrnQ protein in L. lactis, which was shown to contribute to 
BCAA uptake.   
Genes encoding the putative branched-chain amino acid transporters (brnQ) were 
previously identified in a genome-wide screen for CodY targets in S. aureus strain UAMS-1 
(82). The 1356-nucleotide-containing brnQ1 gene encodes a protein of 451 amino acid 
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residues. The brnQ2 gene constitutes of 1278 nucleotides, encoding a 425 amino acid 
protein. Finally, the 1344-nucleotide-containing brnQ3 gene encodes a 447 amino acid 
protein. The specificities of the BrnQ transporters are largely unknown. As a result, 
elucidating the role of these BrnQ transporters in BCAA uptake is key in order to determine 
whether their function plays a role in intracellular BCAA accumulation and, thus, in the 
regulation of CodY.  
 
3.2. Mutation of the brnQ paralogs in S. aureus USA300 
In order to ascertain a function for each of the brnQ paralogs, mutations were 
introduced in each of the three brnQ genes. In-frame markerless brnQ deletions were 
constructed in the brnQ1 and brnQ2 genes using pKOR1 as described above.  A tetracycline 
resistance cassette was inserted into the brnQ3 gene. Finally, a strain was constructed 
ΔbrnQ1,2,3 that contained the mutations in all three of the brnQ genes. See Table 4 for 
details. The mutations were confirmed using PCR amplification across the genes (Fig. 4), and 
the PCR amplicons were sequenced for confirmation.  
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Figure 4. Generation of brnQ mutations in S. aureus strain USA300. Polymerase chain 
reaction analysis confirms the presence of brnQ genes in wild type USA300 and their 
absence in the mutant.  Lanes 1, 3, and 5 illustrate amplified regions of brnQ1, brnQ2, and 
brnQ3 in WT. Lanes 2, 4, and 6 illustrate amplified regions of brnQ1, brnQ2, and brnQ3 in 
the ΔbrnQ123 mutant, where brnQ3 is replaced with a tetracycline-resistance cassette in the 
mutant (as shown with amplicon in lane 6 with a higher molecular weight compared to WT). 
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3.3. Characterization of BrnQ transporters 
 In order to characterize the role of BrnQ transporters, radioactive uptake assays were 
performed, as described above, to first determine function and specificity of each transporter. 
This was accompanied by growth assays, which were conducted to determine if there were 
any growth deficiencies due to lack of any of the brnQs. 
 
3.3.1. Detection of a BCAA uptake deficiency in the USA300 
brnQ123 mutant 
Radioactive uptake assays were performed in order to compare uptake of labeled-
BCAAs between WT and brnQ mutants. As previously described, cells were grown in 
complete CDM, and resuspended into CDM without amino acids for uptake experiments. 
Uptake was measured with the addition of either 14C-labeled BCAA alone or 14C-labeled 
BCAA competing with 1000-fold excess of unlabeled BCAA or non-BCAA to the cells. The 
initial attempt to determine a role for BrnQ transporters in BCAA uptake involved examining 
14C-L-Leucine uptake in wild-type versus the brnQ123 mutant. Both WT and ΔbrnQ123 
displayed comparable 14C-L-Leucine uptake (Fig. 5A), suggesting that either the BrnQ 
transporters are not involved in BCAA uptake or, alternatively, that there exists an alternate 
predominant branched-chain amino acid transporter other than the BrnQs whose function 
may have masked a potential uptake deficiency phenotype. In an attempt to eliminate 
background with an alternate transporter, a competing BCAA was used in increasing ratios in 
uptake assays. We measured uptake of labeled leucine in the presence of increasing 
concentrations of unlabeled isoleucine. We observed that while the levels of leucine uptake 
did not decrease substantially in the wild type bacteria, the uptake of leucine by the brnQ123 
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mutant decreased to near zero at a 1:1000 ratio of 14C-labeled-leucine to unlabeled isoleucine 
(Fig. 5, panels B-D). Similar results were seen using 14C-L-Isoleucine and 14C-L-Valine 
(Figures 6 and 7). This result implicated at least one of the BrnQ transporters in leucine 
uptake. Since we were able to outcompete the effects of an unidentified transporter(s) using a 
1:1000 ratio, all subsequent BCAA uptake assays were conducted in similar fashion to 
characterize BrnQ-dependent BCAA uptake.  
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Figure 5. Radioactive uptake assays illustrating the uptake of 14C-L-Leucine in whole 
cells of S. aureus with addition of various ratios of labeled leucine to unlabeled 
isoleucine. A) 14C-L-Leucine alone; B) 1:10 ; C) 1:100; D) 1:1000. Transport assays using 
concentrated samples of cells harvested from the exponential phase of growth in complete 
CDM were performed in the presence of 0.05 μCi 14C-labeled branched-chain amino acid and 
various concentrations of unlabeled branched-chain amino acid. Results are presented as 
mean +/- SD of three independent replicates. 
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Figure 6. Radioactive uptake assays illustrating the uptake of 14C-L-Isoleucine in whole 
cells of S. aureus with addition of various ratios of labeled isoleucine to unlabeled 
valine. A) 14C-L-Isoleucine alone; B) 1:10; C) 1:100; D) 1:1000. Transport assays using 
concentrated samples of cells harvested from the exponential phase of growth in complete 
CDM were performed in the presence of 0.05 μCi 14C-labeled branched-chain amino acid and 
various concentrations of unlabeled branched-chain amino acid. Results are presented as 
mean +/- SD of three independent replicates. 
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Figure 7. Radioactive uptake assays illustrating the uptake of 14C-L-Valine in whole 
cells of S. aureus with addition of various ratios of labeled valine to unlabeled leucine. 
A) 14C-L-valine alone; B) 1:10; C) 1:100; D) 1:1000. Transport assays using concentrated 
samples of cells harvested from the exponential phase of growth in complete CDM were 
performed in the presence of 0.05 μCi 14C-labeled branched-chain amino acid and various 
concentrations of unlabeled branched-chain amino acid. Results are presented as mean +/- 
SD of three independent replicates. 
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3.3.2. BrnQ transporters are not specific for threonine or the 
non-BCAA proline 
Using the same experimental setup described above, we competed labeled BCAAs 
with unlabeled threonine, a precursor in isoleucine biosynthesis, and proline, an unrelated 
non-BCAA to see whether a 1000-fold excess of these two amino acids could affect uptake 
of BCAAs. These two non-BCAAs, when in excess, were unable to outcompete the uptake of 
BCAAs (Figs. 8 and 9), indicating that the BrnQ transporter(s) involved in the observed 
uptake is specific for BCAAs.  
 
3.3.3. The BrnQ transporters depend on proton motive force for 
active transport of BCAAs 
A feature of oxidative phosphorylation and membrane transport is the proton gradient 
across the cytoplasmic membrane. The proton motive force (PMF) thus created is thought to 
drive ATP synthesis during oxidative phosphorylation, and also, by virtue of associated 
exchange diffusion systems, the translocation of solutes and ions. Uncouplers like carbonyl 
cyanide m-chlorophenyl hydrazone (CCCP) cause a collapse in the proton motive force by 
making the cell membrane freely permeable to protons (7, 51). Indeed, sensitivity to CCCP 
can provide a simple test for the dependence of a bacterial transport system on the proton-
motive force (50). To determine whether the observed BrnQ-dependent uptake of BCAAs 
was dependent on PMF, wild type cells were treated with 200 μM of CCCP. Uptake of 
labeled L-isoleucine by wild type was abolished by CCCP treatment (Fig. 10), in agreement 
with the notion that the BrnQ transporters depend on PMF for active transport of BCAAs. 
The same results were also seen with 14C-L-Valine and 14C-L-Leucine (data not shown)	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Figure 8. Excess threonine does not inhibit BrnQ-dependent uptake of BCAAs. Uptake 
assays are shown for WT (open circles) and ΔbrnQ123 (open triangles). Transport assays 
using samples of cells harvested from the exponential phase of growth in complete CDM 
were performed in the presence of 0.05 μCi 14C-labeled branched-chain amino acid and 150 
μM of unlabeled threonine. Results are presented as mean +/- SD of three independent 
replicates. 
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Figure 9. Excess proline does not inhibit BrnQ-dependent uptake of BCAAs. Uptake 
assays are shown for WT (open circles) and ΔbrnQ123 (open triangles). Transport assays 
using samples of cells harvested from the exponential phase of growth in complete CDM 
were performed in the presence of 0.05 μCi 14C-labeled branched-chain amino acid and 150 
μM of unlabeled proline. Results are presented as mean +/- SD of three independent 
replicates. 
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Figure 10. Radioactive BCAA uptake assays illustrating that the uptake of 14C-L-
isoleucine is dependent on PMF. Addition of uncoupler carbonyl cyanide m-chlorophenyl 
hydrazine (CCCP) to WT (closed circles) abolished uptake of labeled BCAA, compared to 
WT without exposure to CCCP (open circles). Transport assays using cells harvested from 
the exponential phase of growth in complete CDM were performed in the presence of 0.05 
uCi 14C-labeled isoleucine with or without pretreatment with 200 μM of CCCP. Results are 
presented as mean +/- SD of three independent replicates. 
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3.3.4. BrnQ1 transports isoleucine, leucine and valine 
The preceding experiments set the conditions to test for the uptake of BCAAs using 
the individual BrnQ mutants in order to determine their specificity and address the question 
of whether there was a predominant BrnQ transporter. As a result, various conditions were 
tested with the addition of each labeled-BCAA mixed with a 1000-fold excess of an 
unlabeled BCAA. The results of a series of uptake assays performed on the brnQ1 mutant 
(Fig. 11) clearly demonstrate that the BrnQ1 transporter is capable of transporting all three 
BCAAs. As illustrated, the brnQ1 mutant shows an uptake deficiency for leucine and valine 
that is comparable to that of the brnQ123 mutant. As previously mentioned, we were able to 
eliminate the background uptake of an alternate transporter with the addition of unlabeled 
BCAA, since the transporter is shown to have a preference for the competing unlabeled 
BCAA due to its excess. As a result, we see an uptake deficiency in both ΔbrnQ1 and 
ΔbrnQ123, and the complementation of BrnQ1 function by overproducing BrnQ1 in ΔbrnQ1 
(via plasmid pSO1) resulted in a strong increase in the uptake rate of 14C-L-Isoleucine, 14C-L-
Leucine, and 14C-L-Valine (see closed symbols in panels A,B, D, E, G, H of Fig. 11). Also of 
note, we observed that the brnQ1 mutant is still able to take up isoleucine in the presence of 
excess competing BCAAs, suggesting that another BrnQ transporter plays a pivitol role in 
isoleucine uptake. When the labeled-BCAA is competing with excess of the same BCAA, 
but in unlabeled form (Fig. 11 panel C, F, and I), this abolishes uptake of the label in all 
strains. This is because the BCAA transporters have a preference for the unlabeled form of 
BCAA only because of its excess. As a result, the unlabeled BCAA in this way is inhibiting 
uptake of the labeled form, more so emphasizing their role in BCAA transport. 
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Figure 11. Radioactive BCAA uptake assays illustrating that BrnQ1 can transport all 
three BCAAs.  WT (open circles); ΔbrnQ1(open squares);  ΔbrnQ1 + pSO1 (closed 
squares); ΔbrnQ123 (open triangles); ΔbrnQ123 + pSO1 (closed triangles). A) Uptake of 
14C-L-Leucine when competing with unlabeled L-Isoleucine B) Uptake of 14C-L-Leucine 
when competing with unlabeled L-Valine; C) Uptake of 14C-L-Leucine when competing with 
unlabeled L-Leucine D) Uptake of 14C-L-Valine when competing with unlabeled L-
Isoleucine; E) Uptake of 14C-L-Valine when competing with unlabeled L-Leucine F) Uptake 
of 14C-L-Valine when competing with unlabeled L-Valine; G) Uptake of 14C-L-Isoleucine 
when competing with unlabeled L-Leucine; H) Uptake of 14C-L-Isoleucine when competing 
with unlabeled L-Valine; I) Uptake of 14C-L-Isoleucine when competing with unlabeled L-
Isoleucine. Transport assays using concentrated samples of cells harvested from the 
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exponential phase of growth in complete CDM were performed in the presence of 0.05 μCi 
14C-labeled branched-chain amino acid and 150 μM of an unlabeled branched-chain amino 
acid. Results are presented as mean +/- SD of three independent replicates. 
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3.3.5. BrnQ2 transports isoleucine 
The same conditions were tested for the BrnQ2 transported as previously described 
for the BrnQ1 transporter. However, as opposed to the brnQ1 mutant, the brnQ2 mutant did 
not show an uptake deficiency for any BCAA (Fig. 12). Based upon the data illustrated, we 
can conclude that BrnQ2 does not play a major role in uptake of either leucine or valine since 
the uptake of these two amino acids was similar in the ΔbrnQ2 and the wild type strains (Fig. 
12). Moreover, although ΔbrnQ2 did not show significant attenuation of isoleucine uptake, 
which was presumably due to the presence of brnQ1, the isoleucine uptake deficiency in 
ΔbrnQ123 was complemented with brnQ2 expressed in trans (closed diamonds, panels G 
and H, Fig. 12).  This is in agreement with the preceding data shown in Fig. 11 illustrating 
that the ΔbrnQ1 strain was still capable of importing isoleucine. Overexpressed brnQ2 in the 
ΔbrnQ123 mutant also demonstrated that BrnQ2 has some specificity for valine (Fig. 12, 
panel E). 
 
3.3.6. BrnQ3 is not a BCAA transporter 
The data presented in Fig. 13 illustrate that we could not demonstrate a role for brnQ3 
in BCAA import in S. aureus. This conclusion is drawn from the fact that import of all 
BCAAs was similar between that of the wild type and brnQ3 mutant strain, and that 
overproduction of brnQ3 in ΔbrnQ123 did not result in any appreciable increase in any 
BCAA uptake (Fig. 13, panels A-I). As a result, the role of BrnQ3 is currently unclear. This 
does not eliminate the transporter from being a non-BCAA transporter, and this remains to be 
tested.  
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Figure 12 . Radioactive BCAA uptake assays illustrating that BrnQ2 protein transports 
isoleucine, and valine to a much lesser extent. WT (open circles); ΔbrnQ2 (open 
diamonds); ΔbrnQ1,2,3 (open triangles); ΔbrnQ123 + pSO2 (closed diamonds). A) Uptake 
of 14C-L-Leucine when competing with unlabeled L-Isoleucine; B) Uptake of 14C-L-Leucine 
when competing with unlabeled L-Valine; C) Uptake of 14C-L-Leucine when competing with 
unlabeled L-Leucine; D) Uptake of 14C-L-Valine when competing with unlabeled L-
Isoleucine; E) Uptake of 14C-L-Valine when competing with unlabeled L-Leucine; F) Uptake 
of 14C-L-Valine when competing with unlabeled L-Valine; G) Uptake of 14C-L-Isoleucine 
when competing with unlabeled L-Leucine; H) Uptake of 14C-L-Isoleucine when competing 
with unlabeled L-Valine; I) Uptake of 14C-L-Isoleucine when competing with unlabeled L-
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Isoleucine. Transport assays using concentrated samples of cells harvested from the 
exponential phase of growth in complete CDM were performed in the presence of 0.05 μCi 
14C-labeled branched-chain amino acid and 150 μM of an unlabeled branched-chain amino 
acid. Results are presented as mean +/- SD of three independent replicates. 
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Figure 13. Radioactive BCAA uptake assays illustrating that the BrnQ3 protein does 
not transport BCAAs. WT (open circles); ΔbrnQ3 (open hexagons); ΔbrnQ123 (open 
triangles); ΔbrnQ123 + pSO3 (closed hexagons). A) Uptake of 14C-L-Leucine when 
competing with unlabeled L-Isoleucine; B) Uptake of 14C-L-Leucine when competing with 
unlabeled L-Valine; C) Uptake of 14C-L-Leucine when competing with unlabeled L-Leucine; 
D) Uptake of 14C-L-Valine when competing with unlabeled L-Isoleucine; E) Uptake of 14C-
L-Valine when competing with unlabeled L-Leucine; F) Uptake of 14C-L-Valine when 
competing with unlabeled L-Valine; G) Uptake of 14C-L-Isoleucine when competing with 
unlabeled L-Leucine; H) Uptake of 14C-L-Isoleucine when competing with unlabeled L-
Valine; I) Uptake of 14C-L-Isoleucine when competing with unlabeled L-Isoleucine. 
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growth in complete CDM were performed in the presence of 0.05 μCi 14C-labeled branched-
chain amino acid and 150 μM of an unlabeled branched-chain amino acid. Results are 
presented as mean +/- SD of three independent replicates. 
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3.3.7. brnQ mutants are defective for growth in media 
containing low concentrations of BCAAs 
It was of interest to examine the growth phenotype of the brnQ mutants. As shown in 
Fig. 14, the growth of wild type USA300, the single brnQ mutants and the triple brnQ 
mutant were comparable in TSB, a rich medium that contains enzymatic digests of casein 
and soybean meal, peptides of different lengths and compositions, and glucose as the carbon 
source. The absence of a growth defect in the mutants in this medium indicates that i) the 
BrnQ transporters do not serve any apparent physiological function during growth under 
nitrogen-rich conditions and ii) that the mutants do not contain other major defects that 
would affect growth in this condition. As a result, to examine a more relevant growth 
scenario for brnQ function, we used a chemically-defined medium containing glucose as a 
carbon source and all 20 amino acids added individually as the sole source of amino acids, 
whereby the concentrations of individual amino acids in the growth medium can be 
modulated. Despite that final biomass for all strains was similar, we observed that ΔbrnQ1 
had a slightly delayed growth profile in CDM (Fig. 15, panel A). Moreover, growth of 
ΔbrnQ123 was even more affected in this medium (Fig. 15, panel A). When the 
concentration of BCAAs and threonine (as mentioned previously, threonine is a precursor for 
isoleucine biosynthesis) was lowered to 0.05% of that in complete CDM (CDM0.05), growth 
of both ΔbrnQ1 and ΔbrnQ123 was hampered (Fig. 15, panel B). The growth defect of both 
ΔbrnQ1 and ΔbrnQ123 was completely complemented back to a wild type profile with the 
addition of brnQ1 in trans (Fig. 15, panel B). This indicates that the presence of the brnQs, 
especially brnQ1, is required for optimal growth of S. aureus in media containing limiting 
concentrations of BCAAs. 
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Figure 14. BrnQ transporters do not serve any apparent physiological function during 
growth under nitrogen-rich conditions. Growth of WT (open circles), ΔbrnQ1 (open 
squares), ΔbrnQ2 (open diamonds), ΔbrnQ3 (open hexagons), and ΔbrnQ123 (open 
triangles) in tryptic soy broth (TSB).  
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Figure 15. BrnQ transporters are required for optimal growth of S. aureus in 
media containing limiting concentrations of amino acids.  Growth of WT (open circles), 
ΔbrnQ1 (open squares), ΔbrnQ2 (open diamonds), ΔbrnQ3 (open hexagons), and 
ΔbrnQ123 (open triangles), along with complemented strains in panel B only, ΔbrnQ1 + 
pSO1 (closed squares), and ΔbrnQ123 + pSO1 (closed triangles), was monitored in complete 
CDM (panel A) and CDM containing BCAAs and threonine added at 0.05% the 
concentration of CDM (CDM0.05) (panel B).  
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3.4. The brnQ1 mutant and brnQ3 mutants are attenuated for 
virulence in a mouse model of bacteremia but the brnQ2 
mutant is hyper-virulent  
As previously mentioned, an important growth limitation in vivo is very low levels of 
free BCAAs. Indeed, the total concentration of BCAAs in human blood (0.3–0.4 mM) is 
relatively low (120). As a result, the ability of S. aureus to scavenge these amino acids in 
environments that contain low concentration of these nutrients would be an important 
adaptation to growth in vivo. Data presented in the preceding section illustrated that the BrnQ 
transporters play a predominant role for growth in nutrient-limited environments, especially 
when the concentrations of BCAAs are very low (See Fig. 15).  
The virulence potential of the single brnQ mutants and the brnQ triple mutant 
compared to the WT strain was assessed in a murine model of bacteremia. 7-week old female 
balb/c mice were challenged with 6.5 x 106 CFU of each strain via tail-vein injection and the 
mice were sacrificed 4 days post-challenge. Bacterial burden was then analyzed in kidneys, 
liver, and hearts from mice that survived the 96-hour experiment. Notably, all mice injected 
with the ΔbrnQ2 mutant strain became extremely sick within 24 hours, showing symptoms 
such as severe weight loss, and lack of locomotion, eating, drinking, and grooming. As a 
result, mice injected with ΔbrnQ2 either died or required sacrifice before the 96-hour 
experimental timeline (Fig. 16). Mice challenged with wild type USA300 and ΔbrnQ1 
mutant all survived the four-day challenge.  
Mice that were injected with the triple mutant lost significantly more weight (~6% 
more) (data not shown), were more stiff, and moved around much less; however, 70% of 
them survived.  
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Mice injected with the brnQ123 mutant demonstrated a higher bacterial burden in 
both the liver and the kidneys compared to those infected with WT. However, we found that 
the single brnQ1 mutant is attenuated in all three organs and the brnQ3 mutant is attenuated 
in both the liver and the heart compared to WT.  
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Figure 16. The brnQ2 mutant is hyper-virulent in vivo. Kaplan–Meier survival curve 
illustrating the percent survival of 10 mice injected with 6-7 x 106 CFU of WT (open circles), 
ΔbrnQ1 (open squares), ΔbrnQ2 (open diamonds), ΔbrnQ3 (open hexagons), or ΔbrnQ123 
(open triangles).  
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Figure 17. Virulence potential of WT vs ΔbrnQ1,2,3, ΔbrnQ1, ΔbrnQ3 in a murine 
model of bacteremia. 7-week old female Balb/c mice were challenged with ≈6-7 106 CFU of 
either WT, ΔbrnQ1, ΔbrnQ3, or ΔbrnQ123. No mice injected with ΔbrnQ2 survived so data 
is not shown. Mice were sacrificed after 4 days of infection. Bacterial counts obtained from 
livers (A), hearts (B) and kidneys (C). Statistical analysis was performed using the Student’s	  unpaired	   t-test. P values denote significant differences from wild type (WT). WT n=10, 
ΔbrnQ1 n=10, ΔbrnQ3 n=8, ΔbrnQ123 n=7. 
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Chapter 4- Discussion 
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The bacterial pathogen S. aureus has the ability to cause a wide variety of infections 
ranging from endocarditis to pneumonia and osteomyelitis. While our knowledge of the 
genetics and physiology of this pathogen is increasing rapidly, we still have a relatively poor 
understanding of S. aureus virulence in vivo. 
The study of BCAA uptake has been studied extensively in gram-negative bacteria 
(74). Through kinetic experiments and genetic studies, it has been shown that BCAAs are 
transported in E. coli (45, 145), S. typhimurium (63), and P. aeruginosa (55) via numerous 
transport systems, composed of membrane-bound carriers and periplasmic binding proteins. 
On the other hand, only one transporter is utilized for the uptake of all three BCAAs in the 
gram-positive bacterium Streptococcus cremoris (31).  
Various transport systems responsible for uptake of essential nutrients by S. aureus 
have been identified; however, no such study has yet been conducted to look at the uptake of 
BCAAs in this bacterium. During infection, the ability of S. aureus to scavenge amino acids 
from the host would emerge as an important adaptation to growth in vivo (22, 87). USA300 is 
not auxotrophic for any of the BCAAs (data not shown), yet intracellular biosynthesis must 
not be enough to fulfill their nutritional needs in an environment such as an abscess, thus 
creating a need for BCAA uptake during infection. 
Screening, via STM, has allowed for the identification of several genes important for 
S. aureus survival in vivo (22, 87). Several virulence genes were identified in these screens; 
however, the largest gene classes represented by these mutants encoded proteins which 
played roles in pathways for cellular metabolism and small-molecule biosynthesis as well as 
cell surface transmembrane proteins involved in small-molecule binding and transport. (14, 
22). Furthermore, mutants with defects in the amino acid and peptide transport, such as the 
Opp transporters, formed a bulk of these attenuated STM isolates (14, 87).  
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In one study, a braB mutant in S. aureus identified through STM was attenuated in a 
mouse model of systemic infection. It was proposed that this transporter might allow the cell 
to scavenge for specific nutrients or cofactors or, potentially function in transport of solutes 
in response to osmotic or other environmental stresses (14). This gene is allelic to S. aureus 
gene, brnQ3, which encodes a 442-amino-acid branched-chain amino acid carrier protein 
with 74% amino acid identity to BraB (14). Two other paralogues of brnQ3 also exist: brnQ1 
and brnQ2, however, the role of all three putative BCAAs transporters in S. aureus has not 
been characterized until this study. 
Briefly, in another study, more than 200 direct CodY targets in S. aureus were 
identified by genome-wide analysis of in vitro DNA binding. Both brnQ1 and brnQ2 were 
shown to be direct targets of CodY and were over-expressed in a codY mutant (82). 
Moreover, branched-chain amino acids play a crucial role in mediating CodY activity, since 
they act as effector molecules to CodY DNA binding. Hence, a lack of intracellular BCAAs 
will affect CodY binding to its target sites. As a result, one should observe an over-
expression of genes involved in virulence and amino acid biosynthesis and transport, thereby 
enhancing S. aureus pathogenesis by allowing it to adapt to nutrient depleted environments.  
Thus, due to the lack of prior studies, our lab was interested in studying the role of 
three putative BCAA transporters in S. aureus and their affect on virulence. In the current 
study, three tightly regulated and conserved genes encoding putative branched-chain amino 
acid transporters, BrnQ1, BrnQ2, and BrnQ3, were cloned, and their role in BCAA uptake 
were functionally characterized. One important question that this research attempted to 
address was the relative contribution of BrnQ1, BrnQ2, and BrnQ3 to BCAA uptake in S. 
aureus. We first generated mutations in each of the brnQ genes and radioactive BCAA 
uptake assays were conducted to determine the specificity of each transporter. When assays 
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were performed only by the addition of labeled-BCAA, we saw that there was no difference 
in uptake between the WT strain and the ΔbrnQ123 that was devoid of all three BrnQ 
transporters. This suggested that even in the absence of the three BrnQ transporters, there is 
an alternate transporter or transporters that are involved in BCAA uptake. However, since the 
focus of the research at the outset was on the BrnQ transporters, we proceeded to determine 
an optimal condition where we can compete out the effects of the alternate transporter and 
determine the function of the BrnQs. As a result, through the addition of a mixture that 
contains labeled-BCAA competing with a 1000-fold excess of unlabeled-BCAA, we were 
able to see a difference in uptake between the WT strain and the ΔbrnQ123 strains, whereby 
the triple mutant was deficient in taking up the labeled-BCAAs but the WT was still capable 
of uptake. This suggested that in both strains, the alternate transporter of BCAA uptake has a 
preference for high concentrations of the unlabeled BCAA in the mix, potentially implicating 
it as a low affinity, possibly less selective transporter. Nonetheless, we were able to 
determine that the BrnQ transporters do play a role in BCAA uptake.  
One of the key findings of the study was the identification of the BrnQ1 transporter as 
selective for all three BCAAs based on the data showing that the brnQ1 mutant had a 
significant deficiency in uptake of all three labeled BCAAs, and that brnQ1 in trans resulted 
in uptake of all three BCAAs in both the ΔbrnQ1 and ΔbrnQ123 mutants. L. lactis encodes 
two BCAA transporters, BcaP and BrnQ, where BcaP was shown to be the major BCAA 
carrier in this organism and BrnQ played a smaller role in a part of BCAA uptake. Deletion 
of bcaP along with brnQ, a second low-affinity BCAA permease, reduced the viability of the 
strain. Interestingly, the BrnQ1 protein in USA300 demonstrates 61% identity and 78% total 
similarity to the BrnQ protein in L. lactis, suggesting that BrnQ1 possibly plays a similar role 
to that of a major BCAA carrier. Moreover, we also noted that the ΔbrnQ1 strain showed 
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some uptake of isoleucine, while the triple mutant had a complete deficiency in isoleucine 
uptake. This suggested that another BrnQ transporter played a role in isoleucine transport. 
This was resolved with the data demonstrating that overexpression of plasmid-encoded 
BrnQ2 in ΔbrnQ123 resulted in significantly increased uptake of isoleucine. From our 
uptake assay results, the overexpression of BrnQ3 protein did not have a significant impact 
on the uptake of any BCAA, suggesting that BrnQ3 doesn’t have any major role in BCAA 
uptake. We hypothesize that it can play a potential role in uptake of some non-BCAA, 
although this remains to be tested. As a result, our current understanding on the role of 
BrnQ3 in S. aureus is unclear.  
Another key finding of this study was that the presence of brnQs has a beneficial 
effect on S. aureus growth in CDM containing free amino acids as the sole amino acid source 
(Fig. 15) and that this ability is lost when the cells are exposed to a complex mixture of 
peptides (i.e. TSB; see Fig. 14) present in the medium. When peptides are available, these 
BrnQ transporters are probably unnecessary, since uptake and intracellular cleavage of 
peptides into free amino acids is possibly enough to maintain intracellular BCAA pools. 
These peptides can be substrates for highly efficient transport systems encoded by Opp 
transporters (54). 
Our data suggest that the presence of more than one carrier system exists and enables 
BCAA transport in S. aureus. To identify candidates that could play a potential role in the 
remaining influx of BCAAs, we searched the staphylococcal genome for other putative 
BCAA uptake system genes. The product of gene SAUSA300_2538, a general amino acid 
permease, shares homology with BcaP in L. lactis, illustrating 65% identity and 80% 
similarity (25). Moreover, transcription of this gene, like that of the brnQ genes, is dependent 
on CodY, since its identical homolog, SA2619 also encoding an amino acid permease was 
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shown to be highly overexpressed in a codY mutant in S. aureus UAMS-1 (82). This gene 
may therefore be another important BCAA carrier.  Future work will aim to identify alternate 
genes encoding functional proteins and determine whether they are involved in BCAA 
transport. 
 In our study, the addition of CCCP inhibited active transport of all three BCAAs by 
the WT strain, suggesting that the BrnQ transporters function using proton motive force 
(PMF). This finding is supported by previous research on the effect of proton motive force on 
function of transporters in several Streptococcus species (68, 69). PMF functions as the 
driving force for the translocation of several solutes. Conclusions about the mode of energy 
coupling to solute transport are usually drawn from the effects of uncouplers, ionophores, 
and inhibitors of the membrane-bound H+-translocating ATPase and glycolytic enzymes. 
These compounds usually have an effect on numerous metabolic processes within cells. For 
example, uncouplers, which increase membrane permeability to protons, dissipate the pH 
gradient (ΔpH), causing changes in internal pH and a significant depletion in the ATP pool 
(111). Furthermore, alterations in the ΔpH can result in complex changes that may be due to 
a regulatory effect of the internal pHError! Bookmark not defined.. The CCCP functions 
by making the cell membrane more permeable to protons, causing a collapse in proton 
motive force, thereby hampering BCAA transport. Additional experiments can be conducted 
with the addition of DCCD, which inhibits membrane-bound ATPase and thereby active 
transport. In S. agalactiae for instance, active transport of BCAAs was inhibited by both the 
addition of CCCP and DCCD. This suggested that energy in the form of ATP is coupled to 
transport via the action of ATPase, which couples ATP hydrolysis to the extrusion of protons 
from the cell (85). The subsequent proton extrusion creates a proton motive force that drives 
the energy-dependent transport of BCAAs in accordance with the chemiosmotic concept of 
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Mitchell (7, 90). 
After elucidating the BrnQ transporters as BCAA uptake systems, we wanted to 
address the question of the role of these BrnQ transporters in vivo. Our results show that 
these BrnQ uptake systems play a role in nutrient limited environments when the BCAA 
concentrations are limited. This suggested to us that these transporters may also play a 
pivotal role within the nutrient-limited host, allowing the cells to scavenge these essential 
nutrients. In agreement with this hypothesis, brnQ1 and brnQ3 mutants were attenuated in 
some organs during murine infection. Surprisingly, however, the brnQ2 mutant was 
hypervirulent. This finding was interesting in light of a recent study demonstrating that a 
codY mutant in S. aureus also displayed a hyper-virulent phenotype (93). It was suggested 
that this hyper-virulence in the codY mutant could be attributed to the de-repression of CodY 
target genes, such as agr, where we would expect to see an increase in toxin production (93). 
Although the BrnQ1 transporter also transports isoleucine, BrnQ2 may play a more important 
role in isoleucine transport in vivo. As a result, we hypothesize that the ΔbrnQ2 mutant may 
be displaying a “codY phenotype”, starving the cells for isoleucine and, thus, inactivating the 
repressor state of CodY. Of note, CodY has highest affinity for isoleucine (a BrnQ2 
substrate), and plays the dominant co-regulator role (110).  
The ΔbrnQ123 also showed higher bacterial burden in both the liver and kidneys, 
compared to the wild type. We attribute this to what is likely a complex situation stemming 
from the lack of brnQ1 and brnQ3, which causes attenuation, contrasted with the lack of 
brnQ2 in the mutant, which results in hypervirulence. This may explain why 70% of mice 
injected with ΔbrnQ123 still survived but those that survived were still very sick.  
 
Future Directions 
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 While this research has provided important insight into the process of BCAA-uptake 
in S. aureus, there are several possible avenues of study that would be useful in furthering 
our knowledge of the BrnQ system along with other putative BCAA transporters. One course 
of study will be to identify which BCAAs are responsible for the prolonged lag-phase in the 
CDM0.05. In that experiment, all three branched-chain amino acids, including threonine (since 
it is a precursor for isoleucine synthesis), were depleted in the media and were present in 
very limited concentration. Further growth assays will be conducted to determine if this 
growth phenotype by the brnQ123 strain is due to a depletion of particular BCAAs or the 
limitation of all three including threonine. Additionally, our lab will also be looking into 
characterizing other potential candidates for BCAA transport. As previously mentioned, 
SAUSA300_2538 encodes a putative amino acid permease and it is highly expressed in a 
S.aureus UAMS-1 codY mutant. Our lab will be generating a single mutation as well as a 
strain that carries mutations in all three brnQ genes in the USA300 background and its role in 
BCAA uptake will be further characterized using radioactively labeled-BCAA uptake assays 
and growth assays. In a strain that is negative for all three brnQ genes along with 
SAUSA300_2538, we would expect to see a complete decrease in its ability to take up 
labeled BCAA without a competing unlabeled BCAA.  
Moreover, our lab is in the process of generating a codY mutation in the USA300 
genetic background. We are interested in performing real-time PCR to analyze the expression 
of each of the brnQ genes in order to look at whether the transporters are expressed and up-
regulated in the USA300 codY mutant, due to de-repression of the brnQ target genes. We can 
also look at the expression of a major negatively regulated CodY target gene and compare 
the expression of this gene in the brnQ123 mutant versus the expression in the WT strain, 
thereby allowing us to determine whether CodY activity is affected (over-expressed/ up-
78	  
	  
regulated) in the triple mutant due to a defect in BCAA uptake. This can be assessed when 
cells are grown in CDM with limited concentrations of BCAAs.  
Lastly, our lab is also interested in taking a closer look at the hyper-virulent 
phenotype that is attributed to knocking out brnQ2. This includes looking at the secreted 
protein profile and focusing on the potential increase of toxin production. Moreover, perhaps 
the lack of brnQ2 also has a significant effect on isoleucine uptake in vivo. Since brnQ2 is 
specific for isoleucine uptake, and isoleucine has been shown to be a major ligand for CodY 
in S. aureus, a significant decrease in isoleucine uptake in vivo may also have an effect on 
CodY activity, thereby causing a de-repression of many of its target genes and enhancing 
virulence.  
 
 
 
 
 
  
79	  
	  
REFERENCES 1.	   2003.	   From	   the	   Centers	   for	   Disease	   Control	   and	   Prevention.	   Public	   health	  dispatch:	   outbreaks	   of	   community-­‐associated	   methicillin-­‐resistant	  Staphylococcus	   aureus	   skin	   infections-­‐-­‐Los	   Angeles	   County,	   California,	   2002-­‐2003.	  JAMA	  289:1377.	  2.	   2003.	  Methicillin-­‐resistant	  Staphylococcus	  aureus	  infections	  among	  competitive	  sports	   participants	   -­‐	   Colorado,	   Indiana,	   Pennsylvania,	   and	  Los	  Angeles	  County,	  2000-­‐2003.	  Conn	  Med	  67:549-­‐551.	  3.	   2004.	  National	  Nosocomial	   Infections	   Surveillance	   (NNIS)	   System	  Report,	   data	  summary	   from	   January	   1992	   through	   June	   2004,	   issued	   October	   2004.	   Am	   J	  Infect	  Control	  32:470-­‐485.	  4.	   Anderson	   JJ,	   Oxender	   DL.	   1978.	   Genetic	   separation	   of	   high-­‐	   and	   low-­‐affinity	  transport	   systems	   for	   branched-­‐chain	   amino	   acids	   in	   Escherichia	   coli	   K-­‐12.	   J	  Bacteriol	  136:168-­‐174.	  5.	   Archer	  GL.	  1998.	  Staphylococcus	  aureus:	  a	  well-­‐armed	  pathogen.	  Clin	  Infect	  Dis	  
26:1179-­‐1181.	  6.	   Arsic	   B,	   Zhu	   Y,	   Heinrichs	   DE,	   McGavin	   MJ.	   2012.	   Induction	   of	   the	  staphylococcal	   proteolytic	   cascade	   by	   antimicrobial	   fatty	   acids	   in	   community	  acquired	  methicillin	  resistant	  Staphylococcus	  aureus.	  PLoS	  One	  7:e45952.	  7.	   Asghar	  SS,	  Levin	  E,	  Harold	  FM.	  1973.	  Accumulation	  of	  neutral	  amino	  acids	  by	  Streptococcus	   faecalis.	   Energy	   coupling	   by	   a	   proton-­‐motive	   force.	   J	   Biol	   Chem	  
248:5225-­‐5233.	  8.	   Baba	   T,	   Bae	   T,	   Schneewind	   O,	   Takeuchi	   F,	   Hiramatsu	   K.	   2008.	   Genome	  sequence	  of	  Staphylococcus	  aureus	  strain	  Newman	  and	  comparative	  analysis	  of	  staphylococcal	   genomes:	   polymorphism	   and	   evolution	   of	   two	   major	  pathogenicity	  islands.	  J	  Bacteriol	  190:300-­‐310.	  9.	   Bae	  T,	  Schneewind	  O.	  2006.	  Allelic	  replacement	  in	  Staphylococcus	  aureus	  with	  inducible	  counter-­‐selection.	  Plasmid	  55:58-­‐63.	  10.	   Baggett	  HC,	  Hennessy	  TW,	  Rudolph	  K,	  Bruden	  D,	  Reasonover	  A,	  Parkinson	  
A,	  Sparks	  R,	  Donlan	  RM,	  Martinez	  P,	  Mongkolrattanothai	  K,	  Butler	  JC.	  2004.	  Community-­‐onset	   methicillin-­‐resistant	   Staphylococcus	   aureus	   associated	   with	  antibiotic	   use	   and	   the	   cytotoxin	   Panton-­‐Valentine	   leukocidin	   during	   a	  furunculosis	  outbreak	  in	  rural	  Alaska.	  J	  Infect	  Dis	  189:1565-­‐1573.	  11.	   Baker	  MD,	  Acharya	  KR.	  2004.	  Superantigens:	  structure-­‐function	  relationships.	  Int	  J	  Med	  Microbiol	  293:529-­‐537.	  12.	   Barber	  M,	  Rozwadowska-­‐Dowzenko	  M.	  1948.	  Infection	  by	  penicillin-­‐resistant	  staphylococci.	  Lancet	  2:641-­‐644.	  13.	   Bennett	   HJ,	   Pearce	   DM,	   Glenn	   S,	   Taylor	   CM,	   Kuhn	   M,	   Sonenshein	   AL,	  
Andrew	   PW,	   Roberts	   IS.	   2007.	   Characterization	   of	   relA	   and	   codY	  mutants	   of	  Listeria	   monocytogenes:	   identification	   of	   the	   CodY	   regulon	   and	   its	   role	   in	  virulence.	  Mol	  Microbiol	  63:1453-­‐1467.	  14.	   Benton	  BM,	  Zhang	   JP,	  Bond	  S,	  Pope	  C,	   Christian	  T,	   Lee	  L,	  Winterberg	  KM,	  
Schmid	  MB,	   Buysse	   JM.	  2004.	  Large-­‐scale	   identification	  of	  genes	   required	   for	  full	  virulence	  of	  Staphylococcus	  aureus.	  J	  Bacteriol	  186:8478-­‐8489.	  
80	  
	  
15.	   Bronner	  S,	  Monteil	  H,	  Prevost	  G.	  2004.	  Regulation	  of	  virulence	  determinants	  in	  Staphylococcus	   aureus:	   complexity	   and	   applications.	   FEMS	   Microbiol	   Rev	  
28:183-­‐200.	  16.	   Cheung	   AL,	   Bayer	   AS,	   Zhang	   G,	   Gresham	   H,	   Xiong	   YQ.	   2004.	   Regulation	   of	  virulence	   determinants	   in	   vitro	   and	   in	   vivo	   in	   Staphylococcus	   aureus.	   FEMS	  Immunol	  Med	  Microbiol	  40:1-­‐9.	  17.	   Chintalapati	  S,	  Kiran	  MD,	  Shivaji	  S.	  2004.	  Role	  of	  membrane	  lipid	  fatty	  acids	  in	  cold	  adaptation.	  Cell	  Mol	  Biol	  (Noisy-­‐le-­‐grand)	  50:631-­‐642.	  18.	   Chou	  PY,	  Fasman	  GD.	  1973.	  Structural	  and	  functional	  role	  of	  leucine	  residues	  in	  proteins.	  J	  Mol	  Biol	  74:263-­‐281.	  19.	   Chou	   PY,	   Fasman	   GD.	   1978.	   Empirical	   predictions	   of	   protein	   conformation.	  Annu	  Rev	  Biochem	  47:251-­‐276.	  20.	   Collins	  J,	  Rudkin	  J,	  Recker	  M,	  Pozzi	  C,	  O'Gara	  JP,	  Massey	  RC.	  2010.	  Offsetting	  virulence	  and	  antibiotic	  resistance	  costs	  by	  MRSA.	  ISME	  J	  4:577-­‐584.	  21.	   Corrigan	   RM,	   Foster	   TJ.	   2009.	  An	   improved	   tetracycline-­‐inducible	  expression	  vector	  for	  Staphylococcus	  aureus.	  Plasmid	  61:126-­‐129.	  22.	   Coulter	   SN,	   Schwan	   WR,	   Ng	   EY,	   Langhorne	   MH,	   Ritchie	   HD,	   Westbrock-­‐
Wadman	   S,	   Hufnagle	   WO,	   Folger	   KR,	   Bayer	   AS,	   Stover	   CK.	   1998.	  Staphylococcus	   aureus	   genetic	   loci	   impacting	   growth	   and	   survival	   in	   multiple	  infection	  environments.	  Mol	  Microbiol	  30:393-­‐404.	  23.	   Creighton	   TE.	   1993.	   Proteins:	   Structure	   and	   Molecular	   Properties.	   W.	   H.	  Freeman,	  New	  York.	  24.	   Daum	  RS,	   Ito	  T,	  Hiramatsu	  K,	  Hussain	  F,	  Mongkolrattanothai	  K,	   Jamklang	  
M,	  Boyle-­‐Vavra	   S.	  2002.	  A	  novel	  methicillin-­‐resistance	  cassette	   in	  community-­‐acquired	  methicillin-­‐resistant	  Staphylococcus	  aureus	   isolates	  of	  diverse	  genetic	  backgrounds.	  J	  Infect	  Dis	  186:1344-­‐1347.	  25.	   den	   Hengst	   CD,	   Groeneveld	   M,	   Kuipers	   OP,	   Kok	   J.	   2006.	   Identification	   and	  functional	   characterization	   of	   the	   Lactococcus	   lactis	   CodY-­‐regulated	   branched-­‐chain	  amino	  acid	  permease	  BcaP	  (CtrA).	  J	  Bacteriol	  188:3280-­‐3289.	  26.	   Diekema	  DJ,	  Pfaller	  MA,	  Schmitz	  FJ,	  Smayevsky	  J,	  Bell	  J,	  Jones	  RN,	  Beach	  M,	  
Group	  SP.	  2001.	  Survey	  of	   infections	  due	  to	  Staphylococcus	  species:	   frequency	  of	  occurrence	  and	  antimicrobial	  susceptibility	  of	  isolates	  collected	  in	  the	  United	  States,	   Canada,	   Latin	   America,	   Europe,	   and	   the	  Western	   Pacific	   region	   for	   the	  SENTRY	   Antimicrobial	   Surveillance	   Program,	   1997-­‐1999.	   Clin	   Infect	   Dis	   32	  
Suppl	  2:S114-­‐132.	  27.	   Diep	   BA,	   Gill	   SR,	   Chang	   RF,	   Phan	   TH,	   Chen	   JH,	   Davidson	  MG,	   Lin	   F,	   Lin	   J,	  
Carleton	   HA,	   Mongodin	   EF,	   Sensabaugh	   GF,	   Perdreau-­‐Remington	   F.	   2006.	  Complete	   genome	   sequence	   of	   USA300,	   an	   epidemic	   clone	   of	   community-­‐acquired	  meticillin-­‐resistant	  Staphylococcus	  aureus.	  Lancet	  367:731-­‐739.	  28.	   Diep	  BA,	   Stone	  GG,	  Basuino	  L,	  Graber	  CJ,	  Miller	  A,	  des	  Etages	  SA,	   Jones	  A,	  
Palazzolo-­‐Ballance	  AM,	  Perdreau-­‐Remington	  F,	  Sensabaugh	  GF,	  DeLeo	  FR,	  
Chambers	  HF.	  2008.	  The	  arginine	  catabolic	  mobile	  element	  and	  staphylococcal	  chromosomal	   cassette	  mec	   linkage:	   convergence	  of	   virulence	  and	   resistance	   in	  the	   USA300	   clone	   of	   methicillin-­‐resistant	   Staphylococcus	   aureus.	   J	   Infect	   Dis	  
197:1523-­‐1530.	  29.	   Dill	  KA.	  1990.	  Dominant	  forces	  in	  protein	  folding.	  Biochemistry	  29:7133-­‐7155.	  
81	  
	  
30.	   Dineen	  SS,	  Villapakkam	  AC,	  Nordman	  JT,	  Sonenshein	  AL.	  2007.	  Repression	  of	  Clostridium	  difficile	  toxin	  gene	  expression	  by	  CodY.	  Mol	  Microbiol	  66:206-­‐219.	  31.	   Driessen	  AJ,	  de	  Jong	  S,	  Konings	  WN.	  1987.	  Transport	  of	  branched-­‐chain	  amino	  acids	   in	   membrane	   vesicles	   of	   Streptococcus	   cremoris.	   J	   Bacteriol	   169:5193-­‐5200.	  32.	   Driessen	   AJ,	   Kodde	   J,	   de	   Jong	   S,	   Konings	   WN.	   1987.	   Neutral	   amino	   acid	  transport	   by	   membrane	   vesicles	   of	   Streptococcus	   cremoris	   is	   subject	   to	  regulation	  by	  internal	  pH.	  J	  Bacteriol	  169:2748-­‐2754.	  33.	   Duthie	   ES,	   Lorenz	   LL.	   1952.	   Staphylococcal	   coagulase;	   mode	   of	   action	   and	  antigenicity.	  J	  Gen	  Microbiol	  6:95-­‐107.	  34.	   Ebbighausen	  H,	  Weil	  B,	  Kramer	  R.	  1989.	  Transport	  of	  branched-­‐chain	  amino	  acids	  in	  Corynebacterium	  glutamicum.	  Arch	  Microbiol	  151:238-­‐244.	  35.	   Emmett	  M,	  Kloos	  WE.	  1975.	  Amino	  acid	  requirements	  of	  staphylococci	  isolated	  from	  human	  skin.	  Can	  J	  Microbiol	  21:729-­‐733.	  36.	   Foster	   TJ.	   2005.	   Immune	   evasion	   by	   staphylococci.	   Nat	   Rev	  Microbiol	  3:948-­‐958.	  37.	   Foster	   TJ,	   McDevitt	   D.	   1994.	   Surface-­‐associated	   proteins	   of	   Staphylococcus	  aureus:	  their	  possible	  roles	  in	  virulence.	  FEMS	  Microbiol	  Lett	  118:199-­‐205.	  38.	   Francis	   JS,	   Doherty	   MC,	   Lopatin	   U,	   Johnston	   CP,	   Sinha	   G,	   Ross	   T,	   Cai	   M,	  
Hansel	   NN,	   Perl	   T,	   Ticehurst	   JR,	   Carroll	   K,	   Thomas	   DL,	   Nuermberger	   E,	  
Bartlett	  JG.	  2005.	  Severe	  community-­‐onset	  pneumonia	  in	  healthy	  adults	  caused	  by	   methicillin-­‐resistant	   Staphylococcus	   aureus	   carrying	   the	   Panton-­‐Valentine	  leukocidin	  genes.	  Clin	  Infect	  Dis	  40:100-­‐107.	  39.	   Freese	   E,	   Heinze	   JE,	   Galliers	   EM.	   1979.	   Partial	   purine	   deprivation	   causes	  sporulation	  of	  Bacillus	  subtilis	   in	   the	  presence	  of	  excess	  ammonia,	  glucose	  and	  phosphate.	  J	  Gen	  Microbiol	  115:193-­‐205.	  40.	   Fridkin	  SK,	  Hageman	  JC,	  Morrison	  M,	  Sanza	  LT,	  Como-­‐Sabetti	  K,	  Jernigan	  JA,	  
Harriman	   K,	   Harrison	   LH,	   Lynfield	   R,	   Farley	   MM,	   Active	   Bacterial	   Core	  
Surveillance	   Program	   of	   the	   Emerging	   Infections	   Program	   N.	   2005.	  Methicillin-­‐resistant	   Staphylococcus	   aureus	   disease	   in	   three	   communities.	   N	  Engl	  J	  Med	  352:1436-­‐1444.	  41.	   Gatermann	   S,	   Meyer	   HG.	   1994.	   Staphylococcus	   saprophyticus	   hemagglutinin	  binds	  fibronectin.	  Infect	  Immun	  62:4556-­‐4563.	  42.	   Gladstone	   GP.	   1937.	   The	   nutrition	   of	   Staphylococcus	   aureus:	   nitrogen	  requirements.	  Br	  J	  Exp	  Pathol	  18:322-­‐333.	  43.	   Gladstone	  GP.	  1939.	   Interrelationship	  between	  amino	  acids	   in	  the	  nutrition	  of	  Bacillus	  anthracis.	  Br	  J	  Exp	  Pathol	  20:189-­‐200.	  44.	   Gordon	   RJ,	   Lowy	   FD.	   2008.	   Pathogenesis	   of	   methicillin-­‐resistant	  Staphylococcus	  aureus	  infection.	  Clin	  Infect	  Dis	  46	  Suppl	  5:S350-­‐359.	  45.	   Guardiola	   J,	   De	   Felice	  M,	   Klopotowski	   T,	   Iaccarino	  M.	   1974.	  Multiplicity	  of	  isoleucine,	   leucine,	   and	   valine	   transport	   systems	   in	   Escherichia	   coli	   K-­‐12.	   J	  Bacteriol	  117:382-­‐392.	  46.	   Guardiola	   J,	   Iaccarino	   M.	   1971.	   Escherichia	   coli	   K-­‐12	  mutants	   altered	   in	   the	  transport	  of	  branched-­‐chain	  amino	  acids.	  J	  Bacteriol	  108:1034-­‐1044.	  47.	   Guedon	   E,	   Serror	   P,	   Ehrlich	   SD,	   Renault	   P,	   Delorme	   C.	   2001.	   Pleiotropic	  transcriptional	   repressor	   CodY	   senses	   the	   intracellular	   pool	   of	   branched-­‐chain	  amino	  acids	  in	  Lactococcus	  lactis.	  Mol	  Microbiol	  40:1227-­‐1239.	  
82	  
	  
48.	   Guedon	  E,	  Sperandio	  B,	  Pons	  N,	  Ehrlich	  SD,	  Renault	  P.	  2005.	  Overall	  control	  of	  nitrogen	  metabolism	   in	  Lactococcus	   lactis	  by	  CodY,	   and	  possible	  models	   for	  CodY	  regulation	  in	  Firmicutes.	  Microbiology	  151:3895-­‐3909.	  49.	   Handke	  LD,	   Shivers	  RP,	   Sonenshein	  AL.	  2008.	  Interaction	  of	  Bacillus	  subtilis	  CodY	  with	  GTP.	  J	  Bacteriol	  190:798-­‐806.	  50.	   Harold	  FM.	  1975.	  On	  the	  diversity	  of	  links	  between	  transport	  and	  metabolism	  in	  bacteria.	  Molecular	  Aspects	  of	  Membrane	  Phenomena:266-­‐277.	  51.	   Harold	   FM,	   Baarda	   JR.	   1968.	   Inhibition	   of	   membrane	   transport	   in	  Streptococcus	   faecalis	   by	   uncouplers	   of	   oxidative	   phosphorylation	   and	   its	  relationship	  to	  proton	  conduction.	  J	  Bacteriol	  96:2025-­‐2034.	  52.	   Heinemann	   M,	   Kummel	   A,	   Ruinatscha	   R,	   Panke	   S.	   2005.	   In	   silico	   genome-­‐scale	   reconstruction	   and	   validation	   of	   the	   Staphylococcus	   aureus	   metabolic	  network.	  Biotechnol	  Bioeng	  92:850-­‐864.	  53.	   Hendriksen	  WT,	   Bootsma	   HJ,	   Estevao	   S,	   Hoogenboezem	   T,	   de	   Jong	   A,	   de	  
Groot	  R,	  Kuipers	  OP,	  Hermans	  PW.	  2008.	  CodY	  of	  Streptococcus	  pneumoniae:	  link	  between	  nutritional	  gene	  regulation	  and	  colonization.	   J	  Bacteriol	  190:590-­‐601.	  54.	   Hiron	   A,	   Borezee-­‐Durant	   E,	   Piard	   JC,	   Juillard	   V.	   2007.	   Only	   one	   of	   four	  oligopeptide	   transport	   systems	   mediates	   nitrogen	   nutrition	   in	   Staphylococcus	  aureus.	  J	  Bacteriol	  189:5119-­‐5129.	  55.	   Hoshino	   T.	   1979.	   Transport	   systems	   for	   branched-­‐chain	   amino	   acids	   in	  Pseudomonas	  aeruginosa.	  J	  Bacteriol	  139:705-­‐712.	  56.	   Hoshino	   T,	   Kose	   K,	   Uratani	   Y.	   1990.	  Cloning	  and	  nucleotide	   sequence	  of	   the	  gene	  braB	  coding	  for	  the	  sodium-­‐coupled	  branched-­‐chain	  amino	  acid	  carrier	   in	  Pseudomonas	  aeruginosa	  PAO.	  Mol	  Gen	  Genet	  220:461-­‐467.	  57.	   Hsueh	  YH,	  Somers	  EB,	  Wong	  AC.	  2008.	  Characterization	  of	  the	  codY	  gene	  and	  its	   influence	   on	   biofilm	   formation	   in	   Bacillus	   cereus.	   Arch	  Microbiol	  189:557-­‐568.	  58.	   Igarashi	   K,	   Kashiwagi	   K.	   1999.	   Polyamine	   transport	   in	   bacteria	   and	   yeast.	  Biochem	  J	  344	  Pt	  3:633-­‐642.	  59.	   Ito	   T,	   Katayama	   Y,	   Hiramatsu	   K.	   1999.	   Cloning	   and	   nucleotide	   sequence	  determination	  of	  the	  entire	  mec	  DNA	  of	  pre-­‐methicillin-­‐resistant	  Staphylococcus	  aureus	  N315.	  Antimicrob	  Agents	  Chemother	  43:1449-­‐1458.	  60.	   Jacobs	  SI,	  Willis	  AT.	  1964.	  Some	  Physiological	  Characteristics	  of	  Neomycin	  and	  Kanamycin-­‐Resistant	   Strains	   of	   Staphylococcus	   Aureus.	   J	   Clin	   Pathol	   17:612-­‐616.	  61.	   Joseph	   P,	   Ratnayake-­‐Lecamwasam	   M,	   Sonenshein	   AL.	   2005.	   A	   region	   of	  Bacillus	   subtilis	   CodY	   protein	   required	   for	   interaction	   with	   DNA.	   J	   Bacteriol	  
187:4127-­‐4139.	  62.	   Kaplan	   SL,	   Hulten	   KG,	   Gonzalez	   BE,	   Hammerman	   WA,	   Lamberth	   L,	  
Versalovic	   J,	   Mason	   EO,	   Jr.	   2005.	   Three-­‐year	   surveillance	   of	   community-­‐acquired	  Staphylococcus	  aureus	   infections	   in	  children.	  Clin	   Infect	  Dis	  40:1785-­‐1791.	  63.	   Kiritani	  K,	  Ohnishi	  K.	  1977.	  Repression	  and	  inhibition	  of	  transport	  systems	  for	  branched-­‐chain	   amino	   acids	   in	   Salmonella	   typhimurium.	   J	   Bacteriol	   129:589-­‐598.	  
83	  
	  
64.	   Kloos	  WE,	  Bannerman	  TL.	  1994.	  Update	  on	  clinical	  significance	  of	  coagulase-­‐negative	  staphylococci.	  Clin	  Microbiol	  Rev	  7:117-­‐140.	  65.	   Kloos	   WE,	   Musselwhite	   MS.	   1975.	   Distribution	   and	   persistence	   of	  Staphylococcus	   and	  Micrococcus	   species	   and	   other	   aerobic	   bacteria	   on	   human	  skin.	  Appl	  Microbiol	  30:381-­‐385.	  66.	   Kloos	  WE,	   Schleifer	  KH.	  1986.	  Genus	  IV	  –	  Staphylococcus,	  Bergey’s	  Manual	  of	  Systemic	  Bacteriology,	  vol.	  2.	  Williams	  and	  Wilkins,	  Baltimore.	  67.	   Kluytmans	   JA,	   Wertheim	   HF.	   2005.	   Nasal	   carriage	   of	   Staphylococcus	   aureus	  and	  prevention	  of	  nosocomial	  infections.	  Infection	  33:3-­‐8.	  68.	   Kobayashi	  H.	  1985.	  A	  proton-­‐translocating	  ATPase	  regulates	  pH	  of	  the	  bacterial	  cytoplasm.	  J	  Biol	  Chem	  260:72-­‐76.	  69.	   Kobayashi	   H,	  Murakami	   N,	   Unemoto	   T.	   1982.	  Regulation	  of	   the	   cytoplasmic	  pH	  in	  Streptococcus	  faecalis.	  J	  Biol	  Chem	  257:13246-­‐13252.	  70.	   Kotzin	   BL,	   Leung	   DY,	   Kappler	   J,	   Marrack	   P.	   1993.	   Superantigens	   and	   their	  potential	  role	  in	  human	  disease.	  Adv	  Immunol	  54:99-­‐166.	  71.	   Kreiswirth	  BN,	  Lofdahl	  S,	  Betley	  MJ,	  O'Reilly	  M,	  Schlievert	  PM,	  Bergdoll	  MS,	  
Novick	   RP.	   1983.	   The	   toxic	   shock	   syndrome	   exotoxin	   structural	   gene	   is	   not	  detectably	  transmitted	  by	  a	  prophage.	  Nature	  305:709-­‐712.	  72.	   Kuroda	  M,	  Ohta	  T,	  Uchiyama	  I,	  Baba	  T,	  Yuzawa	  H,	  Kobayashi	  I,	  Cui	  L,	  Oguchi	  
A,	  Aoki	  K,	  Nagai	  Y,	  Lian	   J,	   Ito	  T,	  Kanamori	  M,	  Matsumaru	  H,	  Maruyama	  A,	  
Murakami	  H,	  Hosoyama	  A,	  Mizutani-­‐Ui	  Y,	  Takahashi	  NK,	  Sawano	  T,	  Inoue	  R,	  
Kaito	  C,	  Sekimizu	  K,	  Hirakawa	  H,	  Kuhara	  S,	  Goto	  S,	  Yabuzaki	  J,	  Kanehisa	  M,	  
Yamashita	  A,	  Oshima	  K,	  Furuya	  K,	  Yoshino	  C,	  Shiba	  T,	  Hattori	  M,	  Ogasawara	  
N,	   Hayashi	   H,	   Hiramatsu	   K.	   2001.	   Whole	   genome	   sequencing	   of	   meticillin-­‐resistant	  Staphylococcus	  aureus.	  Lancet	  357:1225-­‐1240.	  73.	   Kushwaha	   SC,	   Kates	   M.	   1976.	   Nonpolar	   lipids	   of	   a	   halotolerant	   species	   of	  Staphylococcus	  epidermidis.	  Can	  J	  Biochem	  54:79-­‐85.	  74.	   Landick	   R,	   Oxender	   DL,	   Ames	   GFL.	   1984.	   The	   enzymes	   of	   biological	  membranes,	  2	  ed.	  Plenum	  Press,	  New	  York.	  75.	   Layman	  DK,	  Baum	  JI.	  2004.	  Dietary	  protein	  impact	  on	  glycemic	  control	  during	  weight	  loss.	  J	  Nutr	  134:968S-­‐973S.	  76.	   Levdikov	   VM,	   Blagova	   E,	   Colledge	   VL,	   Lebedev	   AA,	   Williamson	   DC,	  
Sonenshein	   AL,	  Wilkinson	  AJ.	  2009.	  Structural	   rearrangement	  accompanying	  ligand	   binding	   in	   the	   GAF	   domain	   of	   CodY	   from	   Bacillus	   subtilis.	   J	   Mol	   Biol	  
390:1007-­‐1018.	  77.	   Levdikov	  VM,	  Blagova	  E,	   Joseph	  P,	  Sonenshein	  AL,	  Wilkinson	  AJ.	  2006.	  The	  structure	   of	   CodY,	   a	   GTP-­‐	   and	   isoleucine-­‐responsive	   regulator	   of	   stationary	  phase	  and	  virulence	  in	  gram-­‐positive	  bacteria.	  J	  Biol	  Chem	  281:11366-­‐11373.	  78.	   Lindsay	   JA,	   Foster	   SJ.	   2001.	   zur:	   a	   Zn(2+)-­‐responsive	   regulatory	   element	   of	  Staphylococcus	  aureus.	  Microbiology	  147:1259-­‐1266.	  79.	   Liu	   GY,	   Essex	   A,	   Buchanan	   JT,	   Datta	   V,	   Hoffman	   HM,	   Bastian	   JF,	   Fierer	   J,	  
Nizet	  V.	  2005.	  Staphylococcus	  aureus	  golden	  pigment	  impairs	  neutrophil	  killing	  and	  promotes	  virulence	  through	  its	  antioxidant	  activity.	  J	  Exp	  Med	  202:209-­‐215.	  80.	   Lopez	   JM,	   Marks	   CL,	   Freese	   E.	   1979.	   The	   decrease	   of	   guanine	   nucleotides	  initiates	  sporulation	  of	  Bacillus	  subtilis.	  Biochim	  Biophys	  Acta	  587:238-­‐252.	  81.	   Lowy	  FD.	  1998.	  Staphylococcus	  aureus	  infections.	  N	  Engl	  J	  Med	  339:520-­‐532.	  
84	  
	  
82.	   Majerczyk	  CD,	  Dunman	  PM,	  Luong	  TT,	  Lee	  CY,	  Sadykov	  MR,	  Somerville	  GA,	  
Bodi	  K,	  Sonenshein	  AL.	  2010.	  Direct	  targets	  of	  CodY	  in	  Staphylococcus	  aureus.	  J	  Bacteriol	  192:2861-­‐2877.	  83.	   Majerczyk	  CD,	  Sadykov	  MR,	  Luong	  TT,	  Lee	  C,	  Somerville	  GA,	  Sonenshein	  AL.	  2008.	   Staphylococcus	   aureus	   CodY	   negatively	   regulates	   virulence	   gene	  expression.	  J	  Bacteriol	  190:2257-­‐2265.	  84.	   Malke	   H,	   Ferretti	   JJ.	   2007.	   CodY-­‐affected	   transcriptional	   gene	   expression	   of	  Streptococcus	  pyogenes	  during	  growth	  in	  human	  blood.	  J	  Med	  Microbiol	  56:707-­‐714.	  85.	   Maloney	  PC,	  Wilson	  TH.	  1975.	  ATP	  synthesis	  driven	  by	  a	  protonmotive	  force	  in	  Streptococcus	  lactis.	  J	  Membr	  Biol	  25:285-­‐310.	  86.	   Martin	  PK,	  Li	  T,	  Sun	  D,	  Biek	  DP,	  Schmid	  MB.	  1999.	  Role	  in	  cell	  permeability	  of	  an	   essential	   two-­‐component	   system	   in	   Staphylococcus	   aureus.	   J	   Bacteriol	  
181:3666-­‐3673.	  87.	   Mei	   JM,	   Nourbakhsh	   F,	   Ford	   CW,	   Holden	   DW.	   1997.	   Identification	   of	  Staphylococcus	  aureus	  virulence	  genes	  in	  a	  murine	  model	  of	  bacteraemia	  using	  signature-­‐tagged	  mutagenesis.	  Mol	  Microbiol	  26:399-­‐407.	  88.	   Miller	   LG,	   Perdreau-­‐Remington	   F,	   Rieg	   G,	   Mehdi	   S,	   Perlroth	   J,	   Bayer	   AS,	  
Tang	   AW,	   Phung	   TO,	   Spellberg	   B.	   2005.	   Necrotizing	   fasciitis	   caused	   by	  community-­‐associated	   methicillin-­‐resistant	   Staphylococcus	   aureus	   in	   Los	  Angeles.	  N	  Engl	  J	  Med	  352:1445-­‐1453.	  89.	   Mitani	  T,	  Heinze	  JE,	  Freese	  E.	  1977.	  Induction	  of	  sporulation	  in	  Bacillus	  subtilis	  by	  decoyinine	  or	  hadacidin.	  Biochem	  Biophys	  Res	  Commun	  77:1118-­‐1125.	  90.	   Mitchell	   P.	   1976.	   Vectorial	   chemistry	   and	   the	   molecular	   mechanics	   of	  chemiosmotic	   coupling:	   power	   transmission	   by	   proticity.	   Biochem	   Soc	   Trans	  
4:399-­‐430.	  91.	   Molle	  V,	  Nakaura	  Y,	  Shivers	  RP,	  Yamaguchi	  H,	  Losick	  R,	  Fujita	  Y,	  Sonenshein	  
AL.	   2003.	   Additional	   targets	   of	   the	   Bacillus	   subtilis	   global	   regulator	   CodY	  identified	   by	   chromatin	   immunoprecipitation	   and	   genome-­‐wide	   transcript	  analysis.	  J	  Bacteriol	  185:1911-­‐1922.	  92.	   Moncada	   S,	   Higgs	   A.	  1993.	  The	  L-­‐arginine-­‐nitric	  oxide	  pathway.	  N	  Engl	   J	  Med	  
329:2002-­‐2012.	  93.	   Montgomery	  CP,	  Boyle-­‐Vavra	  S,	  Roux	  A,	  Ebine	  K,	  Sonenshein	  AL,	  Daum	  RS.	  2012.	   CodY	   deletion	   enhances	   in	   vivo	   virulence	   of	   community-­‐associated	  methicillin-­‐resistant	   Staphylococcus	   aureus	   clone	   USA300.	   Infect	   Immun	  
80:2382-­‐2389.	  94.	   Moran	  GJ,	  Krishnadasan	  A,	  Gorwitz	  RJ,	  Fosheim	  GE,	  McDougal	  LK,	  Carey	  RB,	  
Talan	  DA,	  Group	  EMINS.	  2006.	  Methicillin-­‐resistant	  S.	  aureus	  infections	  among	  patients	  in	  the	  emergency	  department.	  N	  Engl	  J	  Med	  355:666-­‐674.	  95.	   Morfeldt	   E,	   Taylor	   D,	   von	   Gabain	   A,	   Arvidson	   S.	   1995.	   Activation	   of	   alpha-­‐toxin	  translation	  in	  Staphylococcus	  aureus	  by	  the	  trans-­‐encoded	  antisense	  RNA,	  RNAIII.	  EMBO	  J	  14:4569-­‐4577.	  96.	   Morris	   JG,	   Jr.,	   Shay	  DK,	   Hebden	   JN,	  McCarter	   RJ,	   Jr.,	   Perdue	   BE,	   Jarvis	  W,	  
Johnson	  JA,	  Dowling	  TC,	  Polish	  LB,	  Schwalbe	  RS.	  1995.	  Enterococci	  resistant	  to	   multiple	   antimicrobial	   agents,	   including	   vancomycin.	   Establishment	   of	  endemicity	  in	  a	  university	  medical	  center.	  Ann	  Intern	  Med	  123:250-­‐259.	  
85	  
	  
97.	   Mukhopadhyay	   K,	   Whitmire	   W,	   Xiong	   YQ,	   Molden	   J,	   Jones	   T,	   Peschel	   A,	  
Staubitz	  P,	  Adler-­‐Moore	  J,	  McNamara	  PJ,	  Proctor	  RA,	  Yeaman	  MR,	  Bayer	  AS.	  2007.	   In	   vitro	   susceptibility	   of	   Staphylococcus	   aureus	   to	   thrombin-­‐induced	  platelet	   microbicidal	   protein-­‐1	   (tPMP-­‐1)	   is	   influenced	   by	   cell	   membrane	  phospholipid	  composition	  and	  asymmetry.	  Microbiology	  153:1187-­‐1197.	  98.	   Novick	   RP.	   2003.	   Mobile	   genetic	   elements	   and	   bacterial	   toxinoses:	   the	  superantigen-­‐encoding	  pathogenicity	  islands	  of	  Staphylococcus	  aureus.	  Plasmid	  
49:93-­‐105.	  99.	   Novick	  RP,	  Ross	  HF,	  Projan	  SJ,	  Kornblum	  J,	  Kreiswirth	  B,	  Moghazeh	  S.	  1993.	  Synthesis	  of	   staphylococcal	  virulence	   factors	   is	   controlled	  by	  a	   regulatory	  RNA	  molecule.	  EMBO	  J	  12:3967-­‐3975.	  100.	   Ohshima	  Y,	  Ko	  HL,	  Beuth	   J,	  Roszkowski	  K,	  Roszkowski	  W.	  1990.	  Biological	  properties	   of	   staphylococcal	   lipoteichoic	   acid	   and	   related	   macromolecules.	  Zentralbl	  Bakteriol	  274:359-­‐365.	  101.	   Otto	   M.	   2009.	   Staphylococcus	   epidermidis-­‐-­‐the	   'accidental'	   pathogen.	   Nat	   Rev	  Microbiol	  7:555-­‐567.	  102.	   Otto	  M,	  Gotz	  F.	  2001.	  ABC	  transporters	  of	  staphylococci.	  Res	  Microbiol	  152:351-­‐356.	  103.	   Panlilio	   AL,	   Culver	   DH,	   Gaynes	   RP,	   Banerjee	   S,	   Henderson	   TS,	   Tolson	   JS,	  
Martone	  WJ.	  1992.	  Methicillin-­‐resistant	  Staphylococcus	  aureus	  in	  U.S.	  hospitals,	  1975-­‐1991.	  Infect	  Control	  Hosp	  Epidemiol	  13:582-­‐586.	  104.	   Park	  JH,	  Lee	  SY.	  2010.	  Fermentative	  production	  of	  branched	  chain	  amino	  acids:	  a	  focus	  on	  metabolic	  engineering.	  Appl	  Microbiol	  Biotechnol	  85:491-­‐506.	  105.	   Patel	   M,	   Waites	   KB,	   Hoesley	   CJ,	   Stamm	   AM,	   Canupp	   KC,	   Moser	   SA.	   2008.	  Emergence	   of	   USA300	   MRSA	   in	   a	   tertiary	   medical	   centre:	   implications	   for	  epidemiological	  studies.	  J	  Hosp	  Infect	  68:208-­‐213.	  106.	   Peake	  SL,	  Peter	  JV,	  Chan	  L,	  Wise	  RP,	  Butcher	  AR,	  Grove	  DI.	  2006.	  First	  report	  of	  septicemia	  caused	  by	  an	  obligately	  anaerobic	  Staphylococcus	  aureus	  infection	  in	  a	  human.	  J	  Clin	  Microbiol	  44:2311-­‐2313.	  107.	   Pelz	   A,	   Wieland	   KP,	   Putzbach	   K,	   Hentschel	   P,	   Albert	   K,	   Gotz	   F.	   2005.	  Structure	   and	   biosynthesis	   of	   staphyloxanthin	   from	   Staphylococcus	   aureus.	   J	  Biol	  Chem	  280:32493-­‐32498.	  108.	   Peng	  HL,	  Novick	  RP,	  Kreiswirth	  B,	  Kornblum	  J,	  Schlievert	  P.	  1988.	  Cloning,	  characterization,	   and	   sequencing	   of	   an	   accessory	   gene	   regulator	   (agr)	   in	  Staphylococcus	  aureus.	  J	  Bacteriol	  170:4365-­‐4372.	  109.	   Petranovic	  D,	  Guedon	  E,	  Sperandio	  B,	  Delorme	  C,	  Ehrlich	  D,	  Renault	  P.	  2004.	  Intracellular	   effectors	   regulating	   the	   activity	   of	   the	   Lactococcus	   lactis	   CodY	  pleiotropic	  transcription	  regulator.	  Mol	  Microbiol	  53:613-­‐621.	  110.	   Pohl	   K,	   Francois	   P,	   Stenz	   L,	   Schlink	   F,	   Geiger	   T,	   Herbert	   S,	   Goerke	   C,	  
Schrenzel	   J,	   Wolz	   C.	   2009.	   CodY	   in	   Staphylococcus	   aureus:	   a	   regulatory	   link	  between	  metabolism	  and	  virulence	  gene	  expression.	  J	  Bacteriol	  191:2953-­‐2963.	  111.	   Poolman	   B,	   Smid	   EJ,	   Konings	   WN.	   1987.	   Kinetic	   properties	   of	   a	   phosphate-­‐bond-­‐driven	   glutamate-­‐glutamine	   transport	   system	   in	   Streptococcus	   lactis	   and	  Streptococcus	  cremoris.	  J	  Bacteriol	  169:2755-­‐2761.	  112.	   Raffi	  HS,	  Bates	  JM,	  Jr.,	  Laszik	  Z,	  Kumar	  S.	  2005.	  Tamm-­‐Horsfall	  protein	  acts	  as	  a	   general	   host-­‐defense	   factor	   against	   bacterial	   cystitis.	   Am	   J	   Nephrol	   25:570-­‐578.	  
86	  
	  
113.	   Rammelkamp	   C,	   Maxon	   T.	   1942.	   Resistance	   of	   Staphylococcus	   aureus	   to	   the	  action	  of	  penicillin.	  Proc.	  Soc.	  Exp.	  Biol	  51:386-­‐389.	  114.	   Ratnayake-­‐Lecamwasam	   M,	   Serror	   P,	   Wong	   KW,	   Sonenshein	   AL.	   2001.	  Bacillus	   subtilis	   CodY	   represses	   early-­‐stationary-­‐phase	   genes	   by	   sensing	   GTP	  levels.	  Genes	  Dev	  15:1093-­‐1103.	  115.	   Riazi	   R,	   Wykes	   LJ,	   Ball	   RO,	   Pencharz	   PB.	   2003.	   The	   total	   branched-­‐chain	  amino	   acid	   requirement	   in	   young	   healthy	   adult	   men	   determined	   by	   indicator	  amino	  acid	  oxidation	  by	  use	  of	  L-­‐[1-­‐13C]phenylalanine.	  J	  Nutr	  133:1383-­‐1389.	  116.	   Sanyal	  D,	  Johnson	  AP,	  George	  RC,	  Cookson	  BD,	  Williams	  AJ.	  1991.	  Peritonitis	  due	  to	  vancomycin-­‐resistant	  Staphylococcus	  epidermidis.	  Lancet	  337:54.	  117.	   Schito	  GC.	  2006.	  The	  importance	  of	  the	  development	  of	  antibiotic	  resistance	  in	  Staphylococcus	  aureus.	  Clin	  Microbiol	  Infect	  12	  Suppl	  1:3-­‐8.	  118.	   Schwalbe	   RS,	   Stapleton	   JT,	   Gilligan	   PH.	   1987.	   Emergence	   of	   vancomycin	  resistance	  in	  coagulase-­‐negative	  staphylococci.	  N	  Engl	  J	  Med	  316:927-­‐931.	  119.	   Sebulsky	   MT,	   Hohnstein	   D,	   Hunter	   MD,	   Heinrichs	   DE.	   2000.	   Identification	  and	   characterization	   of	   a	   membrane	   permease	   involved	   in	   iron-­‐hydroxamate	  transport	  in	  Staphylococcus	  aureus.	  J	  Bacteriol	  182:4394-­‐4400.	  120.	   Shimomura	  Y,	  Yamamoto	  Y,	  Bajotto	  G,	   Sato	   J,	  Murakami	  T,	   Shimomura	  N,	  
Kobayashi	  H,	  Mawatari	  K.	  2006.	  Nutraceutical	  effects	  of	  branched-­‐chain	  amino	  acids	  on	  skeletal	  muscle.	  J	  Nutr	  136:529S-­‐532S.	  121.	   Shivers	   RP,	   Sonenshein	   AL.	   2004.	   Activation	   of	   the	   Bacillus	   subtilis	   global	  regulator	   CodY	   by	   direct	   interaction	   with	   branched-­‐chain	   amino	   acids.	   Mol	  Microbiol	  53:599-­‐611.	  122.	   Short	   SA,	   White	   DC.	   1971.	   Metabolism	   of	   phosphatidylglycerol,	  lysylphosphatidylglycerol,	   and	  cardiolipin	  of	  Staphylococcus	  aureus.	   J	  Bacteriol	  
108:219-­‐226.	  123.	   Skaar	  EP,	  Humayun	  M,	  Bae	  T,	  DeBord	  KL,	  Schneewind	  O.	  2004.	  Iron-­‐source	  preference	  of	  Staphylococcus	  aureus	  infections.	  Science	  305:1626-­‐1628.	  124.	   Skinner	   D,	   Keefer	   CS.	   1941.	   Significance	   of	   bacteremia	   caused	   by	  Staphylococcus	   aureus:	   A	   study	   of	   one	   hundred	   and	   twenty-­‐two	   cases	   and	   a	  review	  of	  the	  literature	  concerned	  with	  experimental	  infection	  in	  animals.	  Arch	  Intern	  Med	  68:851-­‐875.	  125.	   Slack	   FJ,	   Serror	   P,	   Joyce	   E,	   Sonenshein	   AL.	   1995.	   A	   gene	   required	   for	  nutritional	   repression	   of	   the	   Bacillus	   subtilis	   dipeptide	   permease	   operon.	  Mol	  Microbiol	  15:689-­‐702.	  126.	   Smith	  TL,	   Jarvis	  WR.	  1999.	  Antimicrobial	  resistance	  in	  Staphylococcus	  aureus.	  Microbes	  Infect	  1:795-­‐805.	  127.	   Soga	   T,	   Ueno	   Y,	   Naraoka	   H,	   Matsuda	   K,	   Tomita	   M,	   Nishioka	   T.	   2002.	  Pressure-­‐assisted	   capillary	   electrophoresis	   electrospray	   ionization	   mass	  spectrometry	  for	  analysis	  of	  multivalent	  anions.	  Anal	  Chem	  74:6224-­‐6229.	  128.	   Spink	  WW,	   Hall	   WH.	   1945.	   Penicillin	   therapy	   at	   the	   University	   of	  Minnesota	  Hospitals:	  1942-­‐1944.	  Ann	  Intern	  Med	  22:510-­‐525.	  129.	   Stenz	   L,	   Francois	   P,	  Whiteson	   K,	  Wolz	   C,	   Linder	   P,	   Schrenzel	   J.	   2011.	  The	  CodY	  pleiotropic	  repressor	  controls	  virulence	  in	  gram-­‐positive	  pathogens.	  FEMS	  Immunol	  Med	  Microbiol	  62:123-­‐139.	  
87	  
	  
130.	   Tauch	  A,	  Hermann	  T,	  Burkovski	  A,	  Kramer	  R,	  Puhler	  A,	  Kalinowski	  J.	  1998.	  Isoleucine	   uptake	   in	   Corynebacterium	   glutamicum	   ATCC	   13032	   is	   directed	   by	  the	  brnQ	  gene	  product.	  Arch	  Microbiol	  169:303-­‐312.	  131.	   Tegmark	   K,	   Morfeldt	   E,	   Arvidson	   S.	   1998.	   Regulation	   of	   agr-­‐dependent	  virulence	   genes	   in	   Staphylococcus	   aureus	   by	   RNAIII	   from	   coagulase-­‐negative	  staphylococci.	  J	  Bacteriol	  180:3181-­‐3186.	  132.	   Thompson	   J.	   1976.	   Characteristics	   and	   energy	   requirements	   of	   an	   alpha-­‐aminoisobutyric	   acid	   transport	   system	   in	   Streptococcus	   lactis.	   J	   Bacteriol	  
127:719-­‐730.	  133.	   Tojo	   S,	   Satomura	   T,	   Kumamoto	   K,	   Hirooka	   K,	   Fujita	   Y.	   2008.	   Molecular	  mechanisms	   underlying	   the	   positive	   stringent	   response	   of	   the	  Bacillus	   subtilis	  ilv-­‐leu	   operon,	   involved	   in	   the	   biosynthesis	   of	   branched-­‐chain	   amino	   acids.	   J	  Bacteriol	  190:6134-­‐6147.	  134.	   Tu	  Quoc	  PH,	  Genevaux	  P,	  Pajunen	  M,	  Savilahti	  H,	  Georgopoulos	  C,	  Schrenzel	  
J,	  Kelley	  WL.	  2007.	  Isolation	  and	  characterization	  of	  biofilm	  formation-­‐defective	  mutants	  of	  Staphylococcus	  aureus.	  Infect	  Immun	  75:1079-­‐1088.	  135.	   Umbarger	   HE.	   1978.	   Amino	   acid	   biosynthesis	   and	   its	   regulation.	   Annu	   Rev	  Biochem	  47:532-­‐606.	  136.	   Vickers	   AA,	   Chopra	   I,	   O'Neill	   AJ.	   2007.	   Intrinsic	   novobiocin	   resistance	   in	  Staphylococcus	  saprophyticus.	  Antimicrob	  Agents	  Chemother	  51:4484-­‐4485.	  137.	   Vijaranakul	  U,	  Nadakavukaren	  MJ,	  Bayles	  DO,	  Wilkinson	  BJ,	   Jayaswal	  RK.	  1997.	  Characterization	  of	   an	  NaCl-­‐sensitive	   Staphylococcus	   aureus	  mutant	   and	  rescue	   of	   the	   NaCl-­‐sensitive	   phenotype	   by	   glycine	   betaine	   but	   not	   by	   other	  compatible	  solutes.	  Appl	  Environ	  Microbiol	  63:1889-­‐1897.	  138.	   Villapakkam	   AC,	   Handke	   LD,	   Belitsky	   BR,	   Levdikov	   VM,	   Wilkinson	   AJ,	  
Sonenshein	   AL.	   2009.	   Genetic	   and	   biochemical	   analysis	   of	   the	   interaction	   of	  Bacillus	   subtilis	   CodY	  with	   branched-­‐chain	   amino	   acids.	   J	   Bacteriol	  191:6865-­‐6876.	  139.	   von	  Eiff	  C,	  Becker	  K,	  Machka	  K,	  Stammer	  H,	  Peters	  G.	  2001.	  Nasal	  carriage	  as	  a	   source	   of	   Staphylococcus	   aureus	   bacteremia.	   Study	   Group.	   N	   Engl	   J	   Med	  
344:11-­‐16.	  140.	   von	   Eiff	   C,	   Peters	   G,	   Heilmann	   C.	   2002.	   Pathogenesis	   of	   infections	   due	   to	  coagulase-­‐negative	  staphylococci.	  Lancet	  Infect	  Dis	  2:677-­‐685.	  141.	   White	  DC,	  Tucker	  AN.	  1969.	  Phospholipid	  metabolism	  during	  bacterial	  growth.	  J	  Lipid	  Res	  10:220-­‐233.	  142.	   Wilkinson	   BJ.	   1997.	   The	   Staphylococci	   in	   Human	   Diseases,	   Biology.	   Churchill	  Livingston,	  London.	  143.	   Willis	  AT,	  Turner	  GC.	  1962.	  Staphylococcal	  lipolysis	  and	  pigmentation.	  J	  Pathol	  Bacteriol	  84:337-­‐347.	  144.	   Wisplinghoff	  H,	  Rosato	  AE,	  Enright	  MC,	  Noto	  M,	  Craig	  W,	  Archer	  GL.	  2003.	  Related	   clones	   containing	   SCCmec	   type	   IV	   predominate	   among	   clinically	  significant	   Staphylococcus	   epidermidis	   isolates.	   Antimicrob	   Agents	   Chemother	  
47:3574-­‐3579.	  145.	   Wood	  JM.	  1975.	  Leucine	  transport	  in	  Escherichia	  coli.	  The	  resolution	  of	  multiple	  transport	   systems	   and	   their	   coupling	   to	   metabolic	   energy.	   J	   Biol	   Chem	  
250:4477-­‐4485.	  	  
88	  
	  
Curriculum vitae 
 
Name: Sameha Omer 
 
Post Secondary 
education and 
degrees 
 
M.Sc., Microbiology and Immunology, 2013 
• University of Western Ontario, London, Ontario, 
Canada 
• Supervisor: David Heinrichs, Ph.D. 
• Project: Role of branched-chain amino acid 
transporters in Staphylococcus aureus virulence 
 
Hon. B.HSc., Health Sciences, 2010          
• University of Ontario Institute of Technology, 
Oshawa, Ontario, Canada 
• Specialist degree in Medical Laboratory Technology 
 
 
Awards Western Graduate Research Scholarship                2011-2013 
 
 
Committee 
Activity 
UWO Infection and Immunity Research Forum     2011-2013 
organizing committee  
 
UWO Karate Club              2011-2012 
 
 
Academic 
contributions 
Poster:	  Omer,	  S.,	  and	  D.E.	  Heinrichs.	  2013.	  Role	  of	  branched-­‐chain	  amino	  acid	  transporters	  in	  
Staphylococcus	  aureus	  virulence.	  London	  Health	  Research	  Forum,	  London,	  ON.	  
 
 
